New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways by Atto, B et al.
1 
 
New therapeutic targets for the prevention of infectious acute exacerbations of COPD: 
role of epithelial adhesion molecules and inflammatory pathways  
 
Brianna Atto1, Mathew Suji Eapen1, Pawan Sharma1,2, Urs Frey3, Alaina J. Ammit2,4, James 
Markos1,5, Collin Chia1,5, Josie Larby1,5, Greg Haug1,5, Heinrich C. Weber1,6, George 
Mabeza1,6, Stephen Tristram1, Stephen Myers1, Dominic P. Geraghty1, Katie L. Flanagan7,8,9,10, 
Philip M. Hansbro11, Sukhwinder Singh Sohal1  
 
1Respiratory Translational Research Group, Department of Laboratory Medicine, School of 
Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, 
Tasmania, Australia, 7248 
2Woolcock Emphysema Centre, Woolcock Institute of Medical Research, University of 
Sydney, Sydney, NSW, Australia, 2037. 
3University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland. 
4Discipline of Medical Sciences, School of Life Sciences, University of Technology Sydney, 
Sydney, NSW, Australia, 2007, 
5Department of Respiratory Medicine, Launceston General Hospital, Launceston, Tasmania 
7250, Australia. 
6Department of Respiratory Medicine, Tasmanian Health Services (THS), North West 
Hospital, Burnie, Tasmania, Australia  
7Clinical School, College of Health and Medicine, University of Tasmania, Launceston, 
Tasmania, Australia, 7250 
8School of Health and Biomedical Science, RMIT University, Melbourne, Victoria, Australia 
9Department of Immunology and Pathology, Monash University, Melbourne, Victoria, 
Australia. 
10Department of Infectious Disease, Launceston General Hospital, Launceston, Tasmania 
7250, Australia. 
11Centre for Inflammation, Centenary Institute and University of Technology Sydney, Sydney, 
and Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and 
University of Newcastle, Newcastle, NSW, Australia 
 
Corresponding Author 
 
Dr Sukhwinder Singh Sohal 
Respiratory Translational Research Group 
Department of Laboratory Medicine, School of Health Sciences, 
College of Health and Medicine, University of Tasmania 
Locked Bag – 1322, Newnham Drive 
Launceston, Tasmania 7248, Australia 
Telephone number: +61 3 6324 5434 
Email: sssohal@utas.edu.au 
  
2 
 
Abstract  
Chronic respiratory diseases are among the leading causes of mortality worldwide, with the 
major contributor, chronic obstructive pulmonary disease (COPD) accounting for 
approximately three million deaths annually. Frequent acute exacerbations of COPD 
(AECOPD) drive clinical and functional decline in COPD and are associated with accelerated 
loss of lung function, increased mortality, decreased health-related quality of life and 
significant economic costs. Infections with a small subgroup of pathogens precipitate majority 
of acute exacerbations (AE) and consequently constitute a significant comorbidity in COPD. 
However, current pharmacological interventions are ineffective in preventing infectious 
exacerbations and antibiotic therapy is compromised by the rapid development of antibiotic 
resistance. Thus, we need to consider alternative preventative therapies. Pathogen adherence 
to the pulmonary epithelium through host receptors is the prerequisite step for invasion and 
subsequent infection of surrounding structures. Thus, disruption of bacterial-host cell 
interactions with receptor antagonists or modulation of the ensuing inflammatory profile 
present attractive avenues for therapeutic development. This review explores key mediators of 
pathogen-host interactions that may offer new therapeutic targets with the potential to prevent 
viral/bacterial mediated AECOPD. There are several conceptual and methodological hurdles 
hampering the development of new therapies that require further research and resolution. 
 
Key words: chronic obstructive pulmonary disease, exacerbation, infection, inflammation, 
novel therapies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abbreviations: 
COPD  Chronic obstructive pulmonary disease 
AE  Acute exacerbation 
NTHi  Nontypeable Haemophilus influenzae 
HRV  Human rhinovirus 
FEV1  Forced expiatory volume in 1 second 
GOLD  Global Initiative of Chronic Obstructive Lung Disease 
LABA  Long acting β2-adrenergic receptor agonists 
LAMA  Long-acting muscarinic antagonists 
ICS  Inhaled corticosteroids 
EC  Electronic cigarettes 
PAFr  Platelet-activating receptor 
pCHo  Phosphorylcholine 
CSE  Cigarette smoke extract 
ICAM-1 Intracellular adhesion molecule-1 
NF-κβ  Nuclear factor-kappaB 
IL  Interleukin 
IFNγ  Interferon gamma  
TNF  Tumor necrosis factor 
hpBECs Primary human bronchial epithelial cells  
RSV  Respiratory syncytial virus 
NHBE  Normal human bronchial epithelial cells  
CEACAM-1 Carcinoembryonic antigen-related cell adhesion molecule-1 
TLR  Toll-like receptor 
UspA1  Ubiquitous surface protein A1 
LPS  Lipopolysaccharide 
LOS  Lipooligosaccharide 
OMP  Outer membrane protein 
PDE  Phosphodiesterase 
IPF  Interstitial pulmonary fibrosis 
CF  Cystic fibrosis 
ROS  Reactive oxygen species 
NOX  NADPH oxidase 
DUOX  Dual oxidase 
Gpx  Glutathione peroxidase 
SOD  Superoxide dismutase  
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RESPIRATORY INFECTIONS ARE A MAJOR DETERMINANT OF PULMONARY 
MORBIDITY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
 
Chronic respiratory diseases are among the leading causes of mortality worldwide, with the 
major contributor, COPD, accounting for approximately three million deaths annually [1-4]. 
Acute exacerbations of COPD (AECOPD) are most often precipitated by respiratory tract 
infections, and are associated with accelerated loss of lung function, increased mortality, 
decreased health-related quality of life and significant economic costs [1, 3, 5-11]. However, 
as is the case for many chronic respiratory diseases, the mechanisms that promote increased 
susceptibility of COPD patients to infections are poorly understood [12-14]. 
 
Recurrent acute infections with bacterial and/or viral pathogens are strongly linked with the 
occurrence of exacerbations and contribute considerably to the clinical course of COPD. As 
such, these infections constitute a significant comorbidity in COPD [15]. Approximately 50% 
of AECOPD are caused by bacterial pathogens and in severe exacerbations requiring 
ventilatory support, the frequency exceeds 70% [12, 13]. In AECOPD, nontypeable 
Haemophilus influenzae (NTHi) is the most frequent bacterium isolated, followed 
by Streptococcus pneumoniae and Moraxella catarrhalis. In healthy individuals and stable 
COPD, these bacteria are common colonisers of the nasopharynx and migration to privileged 
anatomical sites is typically facilitated by a combination of bacterial pathogenic mechanisms 
and defects in host innate immune defences [16-18].  
 
Despite enhanced expression of an antiviral immune response, COPD epithelial cells exhibit 
increased vulnerability to viral infection [19]. PCR-based studies have detected viral 
contribution in 34-60% of cases, most frequently with human rhinoviruses (HRV) accounting 
for 36-50% of viruses [20-23]. Influenza virus and respiratory syncytial virus (RSV) are also 
detected in approximately 16% and 29% of exacerbations, respectively [22]. Viral and bacterial 
co-infection is a frequent occurrence and is strongly associated with worse exacerbations of 
respiratory disease and enhanced inflammation [3, 24, 25]. 
 
The healthy human bronchial tree and lung parenchyma have a remarkable ability to maintain 
a healthy status in spite of repeated exposure to microbial aspiration [15]. However, in COPD 
this innate lung defence appears to be disrupted, enabling proliferation of a dysbiotic lung 
microbiome [26-29]. Pathogen adherence to the pulmonary epithelium through host receptors 
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is the pre-requisite step for migration and subsequent infection of surrounding structures [30]. 
After attachment to the mucosal surface, pathogens use a variety of mechanisms to enhance 
their persistence such as antigenic variation, immune evasion and invasion of host respiratory 
cells [3, 31-33]. Persistence of pathogens in the lower respiratory tract has significant 
implications for patients with COPD and has been suggested to be a major determinant of 
pulmonary morbidity or a source of infections that induce AECOPD [7, 18, 28]. Interestingly, 
even in the absence of clinical exacerbations, airway colonisation by bacterial pathogens in 
COPD has been associated with a clinically significant increase in daily symptoms [3, 34, 35]. 
Thus, elucidating key mediators of pathogen-host interactions may reveal new therapeutic 
targets with the potential to prevent viral/bacterial mediated exacerbations in COPD. 
 
CURRENT COPD MANAGEMENT NECESSITATES ALTERNATIVE 
PREVENTATIVE STRATEGIES 
 
Management of COPD typically involves avoidance of risk factors to prevent disease 
progression and pharmacotherapy to control symptoms, exacerbation rates and severity [2]. 
Existing therapies are of limited effectiveness and do not affect the overall course of COPD. 
Despite prescription of therapies shown to reduce exacerbation frequency, approximately one-
third of COPD patients still experience one or more exacerbations every year [36, 37]. 
 
Loss of lung function and disease progression is exemplified by declines in forced expiatory 
volume in 1 second (FEV1) over time, and frequency of exacerbations [38]. However, it is 
important to consider the inherent limitations of measuring these disease features. FEV1 
measurement requires an artificial manoeuvre that does not always correlate with clinically 
relevant outcomes such as dyspnoea, exacerbations, health status or exercise capacity [38]. 
There is also no standardised definition of an exacerbation; differential diagnoses such as 
pneumonia, heart failure, ischaemic heart disease and pulmonary embolism have to be taken 
into account [39]. These limitations make comparative evaluations of clinical studies difficult. 
This is further complicated by the lack of established biomarkers that reflect the inflammatory 
and destructive process in the lung or that indicate responsiveness to treatment [40, 41]. 
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Pharmacotherapy 
The most widely adopted therapeutic approach for managing COPD are the recommendations 
of the Global Initiative of Chronic Obstructive Lung Disease (GOLD). The GOLD approach 
recommends combination therapy with long acting β2-adrenergic receptor agonists (LABAs), 
long-acting muscarinic antagonists (LAMAs) and inhaled corticosteroids (ICSs) for patients 
with severe disease or frequent exacerbations [42]. LABAs and LAMAs achieve 
bronchodilation to increase lung function parameters such as FEV1 while ICSs are administered 
for their anti-inflammatory effects [43]. Although these treatments may be effective in 
improving quality of life, FEV1 and reduce exacerbation rates, there is currently no conclusive 
evidence that any existing medications for COPD modify mortality rates or the long-term 
decline in lung function [44-48]. The highly variable nature of responses to pharmacological 
treatment has further complicated treatment options. Irrespective of symptom severity and/or 
the level of risk, patients do not respond equally to all drugs [49]. The GOLD approach attempts 
to address this by stratifying patients into phenotypes based on disease severity, assessed by 
spirometry, symptoms and exacerbation history, to determine the most appropriate therapy. 
However, these clinical phenotypes require prospective validation regarding their prognostic 
value and treatment responses [50]. 
 
The anti-inflammatory effects of ICS therapy is important in the management of mild-moderate 
persistent asthma [14, 51], however; the role of ICS in the treatment of COPD remains 
controversial [52]. The inflammatory process in COPD has been shown to be fundamentally 
different to that of asthma [53], and there is conflicting evidence surrounding the efficacy of 
ICSs in preventing exacerbations [42, 54]. Double-blind placebo-controlled studies found that 
even high doses of ICS do not reduce inflammatory cell numbers, concentrations of cytokines, 
or proteases [55-57]. Additionally, early trials found no clinical benefit of long-term ICS in the 
treatment of mild-advanced COPD [58, 59]. Despite this, several trials revealed some benefit 
of ICS treatment showing a reduction in the overall frequency of AECOPD [47, 60-62]. 
However, it has been suggested these conclusions were based upon questionable statistical 
analyses and that other studies that used potentially more appropriate statistical approaches 
found no significant effects of ICS treatment [63-65]. Those that did find a reduction in 
exacerbations, had no significant effect on the survival of COPD patients [66]. These 
inconsistencies may be confounded by large patient-to-patient variability in responsiveness to 
ICS treatment [67], or difficulties in measuring ICS efficacy, particularly as commonly used 
variables such as FEV1 may not adequately reflect the overall health status of patients [48, 50, 
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68]. Additionally, the use of ICS is associated with adverse effects such as bruising, accelerated 
bone loss, and increased risk of subcapsular cataracts [69]. Recent GOLD recommendations 
propose an individualised approach to ICS administration to mitigate the associated risks in 
patients unlikely to benefit from this treatment. Data modelling shows that blood eosinophilia 
may be predictive of a higher risk of exacerbations [70] and a favourable response to ICS 
therapies in patients with stable and moderate-severe COPD [71-75]. This evidence has formed 
the basis for a predictive (>300 cells/uL) threshold which can be used to identify patients with 
the greatest likelihood of treatment benefit with ICSs (in combination with LABAs). ICS-
containing regimes have little or no effect at a blood eosinophil count <100cells/uL [76]. 
Although studies assessing the benefit of ICS treatment in eosinophilic COPD consistently 
report a reduction in exacerbation frequency, they are all based on retrospective evidence [72, 
75]. Thus, clinical trials are required to validate these benefits and elucidate underlying 
mechanisms.  
 
The clinical use of ICS is based on the supposition that airway wall inflammation is a primary 
driver of disease progression, a paradigm that now being challenged [77-81]. Recent evidence 
suggests the contrary, whereby COPD lungs exhibit dysfunctional immune responses due to 
decreases in key immune cells and/or their function [79]. We have previously reported that 
“total” airway wall cellularity decreases in COPD patients compared to never-smokers, with a 
strong association with smoking history [26, 82]. A similar trend was observed for airway wall 
vascularity [83]. Inhaled fluticasone propionate did not change total airway wall cellularity but 
improved lamina propria vascularity in COPD ex-smokers [82, 83]. Our data from a 
confirmatory cross-sectional study demonstrated hypocellularity of both large and small airway 
walls in COPD compared to never-smokers. However, there was no change in the proportions 
of key immune cell populations such as neutrophils, macrophages (CD68+), CD8+ and CD4+ 
cells [26]. The only increase was observed for CD8+ cells in small airways but not in the large 
airways of COPD [26]. In addition, we noted that CD68+ expression was non-specific and 
localised to macrophages and a mesenchymal cell population [26]. We further identified 
differential macrophage switching in small airway wall, lumen and alveolar macrophages 
(AMs) [84]. The airway wall in never-smokers was predominantly M2 (CD163+), which 
switched to a more M1 phenotype (CD68+ iNOS+ dual positive) in COPDs, while, the AMs 
in contrast switched towards a more M2 phenotype. Furthermore, AMs from COPD patients 
had comparatively reduced iNOS expression than never-smokers, again confirming immune 
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dysfunction and possibly explaining their inability to mount an effective response to infection 
and efferocytosis [85].  
 
Thus, the immune-inhibitory function of ICSs may exacerbate the inherent immune 
dysfunction and increase susceptibility to persistent infections [77]. This may explain the 
increased incidence of pneumonia in ICS users compared to non-users [42, 86, 87]. Several 
studies have associated ICS use with a 70% increase in the risk of being hospitalised for 
pneumonia, the effect of which is ICS dose-dependent [42, 69, 86, 87]. This association is 
strengthened by a recent study of over 10,000 COPD patients that compared a fifty-two-week, 
once-daily combination of fluticasone furoate (ICS), umeclidinium (LAMA) and vilanterol 
(LABA) either in triple or dual therapy. There was a higher incidence of pneumonia in the 
triple therapy (ICS-LABA-LAMA) and fluticasone furoate-vilanterol (ICS-LABA) groups 
than in the umeclidium-vilantrol (LAMA-LABA) group [88]. A recent study also found a 37% 
decrease in the risk of pneumonia in patients withdrawn from ICS therapy over three-six 
months [89]. Experimental mouse models have also described ICS-mediated impairment of 
macrophage bactericidal properties and the IFN-mediated antiviral immune response, resulting 
in impaired clearance of pneumococci, Klebsiella pneumoniae [90, 91] and HRV [92]. Despite 
the predictiveness of eosinophilia in ICS treatment response, a meta-analysis of five studies 
comprising of 12, 496 patients with moderate-to-severe COPD showed an increase in the risk 
of pneumonia in the high eosinophil group with ICS-including treatments, compared to the low 
eosinophil group [72]. This indicates that the risk of pneumonia is a result of ICS treatment, 
irrespective of eosinophil count [74, 75, 93]. Proposed drugs targeted against eosinophil 
recruitment by antibody inhibition of IL-5, such as Mepolizumab may therefore be ineffective 
in reducing pneumonia and infectious exacerbations. Indeed, trials have found no beneficial 
effects of IL-5 inhibitors on pneumonia or infectious exacerbations [94-96] and may even be 
detrimental. Eosinophils have been shown to contribute to the immune response against 
infection and counts ≥2% predicted an overall lower risk of bacterial presence at exacerbation 
[70, 97-99]. Therefore, their inhibition may increase susceptibility to infectious exacerbations.  
 
Clinical and experimental studies suggest that there are ICS intra-class differences regarding 
pneumonia risk with some evidence of increased risk with fluticasone propionate (43-78%) 
compared to budesonide therapy [100]. Such disparity may be the consequence of 
physiochemical and pharmacokinetic differences resulting in the prolonged presence of slowly 
dissolving fluticasone propionate particles in the airway epithelial lining fluid compared with 
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budesonide. This may cause protracted local immunosuppression that could impair the 
clearance of airway pathogens, leading to their airway/lung colonisation, which may develop 
into pneumonia. The correlation between higher bacterial load and higher ICS dose in stable 
COPD patients exemplified this theory [100]. Current therapies and clinical trials in COPD are 
summarised in Table 1.  
 
The role of antibiotics 
Although first-line pharmacological interventions reduce AECOPD, they are not an effective 
means of preventing infectious exacerbations [101]. Thus, current guidelines advocate the use 
of intermittent antibiotic therapy for moderate and severe exacerbations that exhibit symptoms 
consistent with respiratory infection, i.e. increase in dyspnoea, sputum volume and sputum 
purulence [42]. Usual initial empirical treatment is aminopenicillin with clavulanic acid, 
doxycycline or macrolide treatment due to their additional anti-inflammatory properties [36, 
102]. Studies suggest that long-term or intermittent antibiotic therapy may have a beneficial 
effect on the outcome of COPD patients and may improve quality of life by reducing 
exacerbation frequency or by prolonging time to next exacerbation through local and systemic 
effects [103-107]. Antibiotic therapy may reduce exacerbation frequency by eradicating 
colonising bacteria with the potential to cause infection, however there is limited information 
to support this hypothesis [35]. This hypothesis is also not correlated with microbiome data 
that show an overrepresentation of potential pathogens and associated inflammatory response 
in COPD airways despite antibiotic therapy [18, 28, 29, 108]. 
 
Antibiotic therapy is complicated by the lack of guidelines pertaining to the most appropriate 
drug and administration regime, as well as the optimal duration of therapy [101]. Furthermore, 
antibiotics do not offer long-term protection against re-infection and relapse is common [109]. 
Inadequate antibiotic efficacy, which through incomplete resolution of the initial exacerbation 
and persistent bacterial colonisation is likely to influence risk of relapse [35, 110, 111]. 
Prolonged and sub-inhibitory antibiotic concentrations in COPD airways may also promote 
antibacterial resistance by providing a conducive environment for the amplification of 
antibiotic-resistant subpopulations [101, 111]. Management of pneumococcal and NTHi 
infections, have been compromised (in particular NTHi) by the rapid development of antibiotic 
resistance and infections are frequently refractory to first and second line antibiotics [109]. 
Intermittent or long-term use of macrolides and penicillins have been associated with the failure 
to eradicate resistant strains of S. pneumoniae and H. influenzae from the sputum of COPD 
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patients [35, 102, 111, 112]. Fluoroquinolones, in particular moxifloxacin, have proved to be 
effective at eradicating common COPD pathogens and resistance to this class of antibiotic is 
currently low [102, 113]. However, fluoroquinolone-resistant NTHi isolates have been 
detected worldwide and treatment failure with other fluoroquinolones such as ofloxacin or 
levofloxacin has also been described [114-116]. A randomised control trial reported a direct 
comparison of 13-week antibiotic therapy using tetracyclines, macrolides and quinolones. 
Total bacterial load did not decrease significantly after three months and there was a large 
increase in antibiotic resistance in all treatment groups where mean inhibitory concentrations 
of culture isolates increased by at least three-fold over the placebo group [117]. 
 
Long-term use of particular antibiotics has also been associated with adverse side effects, 
further reducing antibiotic treatment options. For example, azithromycin use has been 
associated with hearing impairment and increases in cardiovascular events [36]. 
 
Vaccination 
Prevention of infectious exacerbations by vaccination has the potential to increase quality of 
life and patient survival. However, the availability of vaccines that protect COPD patients from  
key pathogens is restricted and the efficacy of currently used formulations are variable [118]. 
International guidelines recommend that patients with COPD should be immunized with 
influenza and pneumococcal vaccines. A systematic review of injectable polyvalent 
pneumococcal vaccines in COPD patients identified seven studies for inclusion (2 for 14-valent 
vaccine and 5 for 23-valent) and observed reductions in the incidence of pneumococcal 
pneumonia and AECOPD that did not reach statistical significance [119]. However, the 
pneumococcal conjugate vaccines, PPSV13 and PPSV23, have been shown to reduce the 
incidence of community-acquired pneumonia in COPD patients [120, 121].  
 
The majority of clinical trials evaluating the efficacy of influenza vaccines in COPD patients 
indicate long-term benefits of annual seasonal influenza vaccination, such as reduced 
frequency of exacerbations, reduced hospitalisations and outpatient visits, and decreased all-
cause and respiratory mortality [122-124]. Despite this, patients with COPD still remain highly 
vulnerable to adverse outcomes from influenzae infections. [123, 125]  There is also evidence 
that suggests COPD patients exhibit a significantly lower humoral immune response to the 
influenza vaccination compared to healthy participants. A study assessing the immunogenicity 
of the 2010 trivalent influenza vaccine found a lower rate of seroconversion in COPD 
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participants (43%) compared to healthy participants (90%) [126]. This altered immune 
response was associated with reductions in both T-cell and B-cell function. [127, 128] Further 
investigations are warranted to examine the mechanisms behind this altered immune response 
with the potential for new vaccination approaches in COPD that maximise protection against 
influenza infections.   
 
Development of new vaccination strategies is further complicated by the intrinsic heterogeneity 
of pathogen target proteins, as is the case with an oral whole-cell killed NTHi vaccine 
developed to reduce acute exacerbations in COPD. Trials with this vaccine showed no 
significant beneficial effects to warrant widespread vaccination [7, 129]. Similarly, vaccination 
is not feasible against viruses such as HRV due to the large number of serotypes with low 
antibody cross-reactivity [130]. Despite the feasibility of vaccination, no vaccine is currently 
licensed to prevent RSV infection. [131, 132]. 
 
Antiviral Agents 
Although not currently utilised in COPD, antiviral agents have been suggested as an approach 
to mitigate viral-induced exacerbations and associated complications particularly as there are 
currently no therapies recommended for treatment of viral infections in COPD.  [133, 134]  
Although vaccination may be a useful prophylactic treatment it has no benefit during an active 
infection. 
 
Only two classes of drugs are currently approved for the treatment of influenza: M2 ion channel 
blockers (adamantanes) and neuraminidase (NA) inhibitors. Adamantanes inhibit influenza A 
replication by blocking virus entry while NA inhibitors (e.g., Peramivir, Zanamivir and 
Oseltamivir) block the release of virions after budding from the host cell in both influenza A 
and B viruses [135-138]. Zanamivir has been shown to prevent influenza infection or reduce 
symptoms if begun early in the infection process. The clinical efficacy and safety of Zanamivir 
has been demonstrated in all age groups and in healthy and immunocompromised individuals 
[137, 139-141]. Albeit limited, evidence suggests similar benefits and safety profile of 
Zanamivir for the treatment of influenza in COPD [125]. However, the evidence produced by 
this study was unable to rule out adverse events such as bronchospasm. Zanamivir was shown 
to promote resolution of influenza, without adversely affecting pulmonary function [142]. 
Oseltamivir has shown a similar efficacy to Zanamivir in healthy adults and children with 
reductions in illness severity and duration, viral shedding, and lower respiratory tract 
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complications [143]. Oseltamivir has not been associated with any significant respiratory 
adverse effects in healthy individuals, but no data exists on the safety and efficacy in patients 
with underlying respiratory disease [144, 145]. Likewise, there are no trials of M2 inhibitors in 
COPD patients, however there are serious safety concerns in otherwise healthy patients with 
this class of antiviral. Side effects involving the central nervous system occur in 5%–29% of 
patients treated with amantadine, and include headache, light-headedness, dizziness, difficulty 
in concentrating, and insomnia [142]. 
 
Of growing concern is the reduced susceptibility to currently used antivirals, which has been 
demonstrated in influenza A and B strains. [146, 147]. Clinical cases of influenza viruses 
harbouring single or multiple NA or haemagglutinin (HA) substitutions or deletions have been 
reported [148]. H1N1 influenza viruses containing a mutation conferring resistance to 
oseltamivir, one of the most common resistance mutations seen in treated patients since 2004, 
have now circled the globe [149]. Adamantane resistance increased in frequency from 0.4% of 
influenza A viruses isolated in 1994–1995 to 12.3% in 2003–2004. Of concern is the fact that 
the currently circulating strains of avian H5N1 influenza are highly resistant, thus if human 
infections do become more frequent, the M2 inhibitors will have no useful therapeutic role 
[142]. Combination therapy of antivirals with different mechanisms of action has demonstrated 
greater clinical efficacy than monotherapy [150, 151] and  has been promoted for the treatment 
of strains resistant to one of the NA inhibitors [152]. However, mutations resulting in a cross-
resistant phenotype to Zanamivir and Oseltamivir have been reported and are more likely to 
occur in immunocompromised individuals. [147, 153]. While these resistant phenotypes tend 
to arise from prolonged treatment with NA inhibitors, it is generally immunocompromised 
patients that required prolonged therapy in the first place. Given that the only approved 
antivirals against influenza are already inducing emergence of resistant mutants, there is an 
urgent need for the development of new antiviral approaches. 
 
A number of other HRV-targeted antiviral agents have been developed but have so far not been 
approved for human use. These agents typically target the HRV capsid to prevent binding to 
host cells, or inhibit viral 3C protease, the activity of which is essential to viral replication [154, 
155]. However, considering these are viral targets and the high mutation rates of RNA viruses, 
the efficacy of these antiviral classes are likely to be undermined by resistant mutants. During 
phase II clinical trials with the capsid binder pleconaril, virus variants with reduced 
susceptibility or even full resistance were detected in, respectively, 11% and 3% of the drug-
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treated subjects. All capsid binders, including vapendavir and pleconaril, share the same target 
so drug-resistant mutants exhibit cross-resistance [133]. Development is further complicated 
by formulation bioavailability and toxicity [133].  
 
Thus, whilst the treatment of viral-induced AECOPD may confer long-term benefits in COPD 
patients, the need for new antiviral targets that will not instigate resistance is needed, 
particularly given the likelihood of prolonged treatment regimens in these patients.  
 
Non-pharmacological therapy  
Non-pharmacological therapy, such as patient education, pulmonary rehabilitation, long term 
oxygen and minimising exposure to particulate matter are also important for improving health-
related quality of life in COPD patients [156, 157]. However, cessation of smoking is one of 
few interventions that slows the rate of progression of COPD and prolongs life expectancy 
[158, 159]. The Lung Health Study, a five-year early intervention study involving 3,926 
smokers with mild to moderate airflow limitation due to COPD demonstrated the benefit of 
sustained smoking cessation. Participants who ceased smoking experienced half the rate of 
decline in FEV1 than continuing smokers, which was comparable to those that had never 
smoked [160]. This benefit persisted for at least an additional six years in those that remained 
abstinent [161]. In addition, smoking cessation, regardless of the severity of lung disease, has 
been shown to have a mortality benefit, secondary to the reduction in cardiovascular and lung 
cancer mortality [162]. The addiction to the nicotine component of tobacco and behavioural 
dependence has resulted in a large proportion (30.4% to 43.0%) of moderate to severe COPD 
patients continuing to smoke [156]. This is in spite of the two-fold increase in smoking 
cessation in patients undergoing nicotine replacement therapy as relapse rates are high in 
COPD compared to the general population [163, 164]. The recommendation of oxygen therapy 
came from early experiments that showed long-term treatment with supplemental oxygen 
reduced mortality among patient with COPD [165]. However, recent studies have refuted the 
benefits of oxygen therapy, finding no effect on survival of COPD patients with moderate 
hypoxemia [165-167]. The Long-Term Oxygen Treatment trial of 738 COPD patients followed 
for 1-6 years, found no significant benefits of long-term oxygen therapy on survival, 
hospitalization rates, exacerbations or other outcomes such as quality of life, lung function and 
exercise capacity [165, 168]. 
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Nicotine replacement therapy can be administered in various formulations such as gums, 
lozenges, transdermal patches, inhalers and nasal sprays. However, each method comes with 
issues regarding nicotine delivery and/or side effects [156]. Electronic cigarettes (EC), have 
gained rapid popularity as a mode of nicotine replacement therapy, with the concept that they 
are a safer alternative to cigarette smoking. Despite their increasing use, there is limited 
research regarding the impact of EC on human health and effects on the lungs [164, 169]. EC 
vapour typically contains nicotine, together with a variety of flavourings, additives, and other 
contaminants that have the potential to affect normal lung biology. They also may be gateway 
formulations to conventional smoking and be particularly deleterious in COPD patients [170]. 
 
Evidence shows that EC aerosols have immune modulatory activity on  human and mouse 
airway epithelial cells in vitro and mice in vivo, resulting in oxidative stress [171], low levels 
of inflammatory cell recruitment [172-174], and DNA damage that reduced repair activity 
[175]. Two-week EC aerosol exposure in mice resulted in reduced bacterial clearance and 
increased susceptibility to influenza virus infection compared to air-exposed controls, despite 
appropriate recruitment of neutrophils and alveolar macrophages. The impaired immune 
defence was attributed to reduced levels of cytokines (IL-17A, IFNγ, and TNF) involved in 
protective immunity against infection. Reduced IL-17 responses and defective bacterial 
phagocytic function of alveolar macrophages has also been observed. Increases in 
phosphatidylinositol 3-kinase, increases in miR-125a/b and impaired stress granule formation 
have all been implicated in increased susceptibility to influenza virus infection in COPD [31, 
176] . Miyashita et al reported that nicotine-containing EC vapour increases primary cell and 
mouse nasal PAFR expression, hence increasing susceptibility to pneumococcal infection 
[177].  
 
It is unclear which component(s) of EC vapour elicits these immunomodulatory effects. 
Nicotine has many immunosuppressive effects, including impairing antibacterial defences 
against S. pneumoniae and Legionella pneumophilia [178, 179], and alteration of macrophage 
activation that suppresses adherence, chemotaxis, phagocytosis and killing of bacteria [180-
182]. The effects of other components on pulmonary function are less clear but constituents 
such as propylene glycol are known to elicit detrimental effects on lung function of workers 
exposed to theatrical smoke machines [183]. In a small study, acute exposure to nicotine-rich 
aerosols in healthy naïve subjects affected the biology of small airway epithelium, alveolar 
macrophages and the alveolar capillary endothelium. Gene expression changes in small airway 
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epithelium and alveolar macrophages were also observed in the nicotine-free group, suggesting 
that EC vapour may have harmful long-term effects [175]. We recently showed in a ground-
breaking study, that in a manner very similar to cigarette smoke, EC and IQOS (heat-not-burn 
smoking device) has the potential to increase oxidative stress and inflammation, infections, 
airway remodelling and initiate epithelial mesenchymal transition (EMT) related changes in 
the airways of users of these devices. However, prospective clinical studies must be conducted 
to verify our in vitro, cell-based but highly important and novel findings on EC and IQOS 
[184]. 
 
NEW THERAPEUTIC TARGETS FOR THE PREVENTION OF INFECTIOUS 
AECOPD 
 
Microbial pathogenesis involves a number of vital steps in order to infect and survive in the 
host environment. Upon access to the respiratory tract, pathogens must find a way to attach to 
host tissue, avoid destruction by host immune defences and replicate despite harsh 
environmental pressures and antimicrobial therapies (Figure 1). Development of new 
therapeutic agents has focussed on subverting these pertinent steps; inhibition of 
attachment/invasion, disruption of cell membrane, inhibition of microbial replication or 
enhancing clearance by the immune response (Figure1) [185]. The rising concern of antiviral 
and antibiotic resistance has also lead to the focus on specific host cellular processes essential 
for viral replication and modulation of the inflammatory profile in COPD, which is currently 
unresponsive to current pharmacotherapies [186]. These strategies are less likely to induce 
antimicrobial resistance as a missing cellular function is more difficult for a pathogen to adapt 
to, and should affect replication independent of the type, strain and antigenic properties of the 
invading pathogen [138]. New therapeutic targets that mitigate host-pathogen attachment and 
immune subversion have been summarised in Table 2 and Table 3, respectively.   
 
Mediators of pathogen-host cell attachment  
Platelet-activating receptor (PAFr) 
The PAFr is a widespread G protein-coupled receptor that is expressed on the surface of the 
majority of innate immune cells and is a potent mediator of phospholipid-induced inflammation 
[187]. The PAFr recognises the phosphorylcholine (pCHo) determinant on the eukaryotic pro-
inflammatory chemokine PAF, which is synthesised by various cells, such as leukocytes, 
macrophages and platelets [188]. PAFr-PAF binding mobilises Ca2+ and activates numerous 
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signalling pathways, such as those involving phospholipase C and A2, and protein kinase C 
with downstream immune modulatory effects [189, 190]. Like PAF, the cell wall of NTHi and 
S. pneumoniae express pCho residues which engage the PAFr through molecular mimicry and 
induce cytoskeleton remodelling and subsequent host cell internalisation [187, 191]. This 
exploitation confers several persistence-related effects, including adherence, invasion and 
resistance to some host-derived antimicrobials [129, 192-194].  
 
PAFr is of particular interest as cigarette smoke exposure, the major risk factor for the 
development of COPD [5, 187], has been shown to significantly upregulate its expression in 
the airway epithelium [195-198]. Studies have found significant increases in PAFr expression 
in both large and small airway epithelium and alveoli of active smokers and COPD patients, 
suggesting a ubiquitous expression of the receptor throughout the airways. The effect on 
adhesion is not limited to the most distal epithelial cells, since cigarette smoke extract (CSE)-
stimulated adhesion has been shown in the bronchial epithelial cell line (BEAS2-B) and human 
primary bronchoepithelial cells (hpBECs) [195, 197]. Increased PAFr mRNA and protein 
levels in CSE-exposed A549 cells suggests a major role in CSE-induced adhesion [195]. 
Similar mechanisms could also be active in idiopathic interstitial lung disease [199].  
 
Significant increases in S. pneumoniae and NTHi adherence to cultured primary human 
bronchial epithelial cells (hpBECs) exposed to CSE has also been demonstrated [195, 196]. 
Adhesion by these pathogens was attenuated by the PAFr antagonist, WEB-2086, to levels in 
non-CSE-exposed cells [196]. We also found that adhesion was attenuated by a specific PAFr 
antagonist (CV-3988). Compatible with previous studies in cytokine-stimulated A549 cells, 
blocking of PAFr attenuated stimulated, but not unstimulated adhesion of pneumococci to these 
cells [195]. The exact constituents of CSE responsible for PAFr upregulation remains 
unknown. However, a recent study showed upregulation of PAFr expression in nasal 
epithelium in response to nicotine-rich E-cigarette vapour in vitro, suggesting that nicotine may 
be important [200]. 
 
These investigations suggest that the upregulation of PAFr levels on the respiratory epithelial 
cell surface may increase susceptibility to infections in COPD patients [197]. PAFr antagonists 
may therefore be a new drug target for inhibiting PAFr-dependent respiratory infections in 
smokers and COPD patients [196]. The PAFr bacterial ligand, PCho would be a poor vaccine 
target for NTHi given the constant phase variation and variable nature in which it stimulates 
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protective immunity [192, 201]. However, it may be more promising if combined with 
immunogens (e.g. proteins) that are conserved across NTHi strains.  
 
Intracellular adhesion molecule-1 (ICAM-1; CD54) 
ICAM-1 is expressed constitutively on a wide variety of cells and is a key molecule in processes 
critical to normal leukocyte recruitment and T-cell development such as reversible cell-cell 
adhesion that enables intercellular communication and signal transduction [202]. Additionally, 
aberrant ICAM-1 levels have been implicated in pathological complications such as acquired 
immunodeficiency syndrome, malignancies and allergic asthma [203]. NTHi and 60-90% of 
HRV serotypes utilise ICAM-1 in attaching to host bronchial and alveolar epithelial cells [204-
206]. More data are required to determine the frequency at which NTHi uses this mechanism 
of adhesion. However, blockade of cell surface ICAM-1 with a specific antibody reduced the 
adhesion of NTHi to A549 respiratory epithelial cells by 37% and to CHO-ICAM-1 cells by 
69%; suggesting a cell-dependent role of ICAM-1 as a binding target [202]. 
 
Evidence suggests that expression of ICAM-1 is stimulated via the activation of nuclear factor-
kappa-B (NF-κβ) pathways by NTHi and HRV [207]. We previously reported increased 
ICAM-1 levels on the airway epithelium of patients with chronic bronchitis and smoking-
related chronic airflow limitation [208]. In vitro, incubation of respiratory epithelial cells with 
NTHi increased ICAM-1 expression four-fold and the binding of HRV39 in a TNF-dependant 
manner [129, 202, 205, 209]. Additionally, all HRV serotypes, regardless of the receptor used 
for cell attachment, have been shown to enhance ICAM-1 expression [207]. This suggests a 
mechanism for additive or synergistic effects between bacterial and viral infection that may 
explain why COPD patients are more susceptible to viral infections and NTHi-HRV co-
infections [209].  
 
Vaccine development against NTHi and HRV infections is difficult given the high degree of 
antigenic heterogeneity. Antibodies produced in response to vaccines provide little or no cross-
protection against newly-acquired strains [201, 210]. This makes host ICAM-1 an enticing 
therapeutic target for the prevention of both NTHi and HRV infection in COPD patients. 
However, inhibiting ICAM-1 may induce deficient normal host defences and cell trafficking 
as a side-effect. One trial assessed this using a mouse anti-human ICAM-1 antibody (14C11) 
that specifically binds domain 1 of human ICAM-1. When administered topically or 
systemically, the antibody prevented the entry of two major groups of HRVs and reduced 
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cellular inflammation, pro-inflammatory cytokine production and virus load in vivo [211]. 
Inhibiting ICAM-1, therefore, offers a promising means of supressing HRV entry and may also 
have application in preventing the common cold and exacerbations of bronchiolitis, asthma, 
COPD and pneumonia in patients [210, 212]. 
 
NTHi ligands for ICAM-1, namely the outer membrane protein P5 fimbria and the type IV 
pilin, PilA, have also been investigated as potential therapeutic targets [129, 205]. Expression 
of PilA contributes significantly to ICAM-1-mediated adherence and mucosal colonisation and 
also has important roles in biofilm formation and the ability of NTHi to exhibit competence 
[213]. Each of these phenotypes has important implications for the initiation and establishment 
of long-term colonization of humans, as well as ability to induce disease, cause recurrence and 
promote the chronicity of NTHi-induced diseases [205]. It has also been shown that respiratory 
syncytial virus (RSV) enhances the attachment of NTHi to epithelial cells which is largely 
mediated by the bacterium’s P5-fimbria-binding receptors [214]. 
 
NTHi PilA may also be a therapeutic target. Disruption of the pil locus diminished the ability 
of NTHi to adhere to normal human bronchial epithelial cells (NHBEs) in vitro or to form 
stable, robust biofilms in a continuous flow chamber. Additionally, a pilA mutant was not as 
capable of maintaining colonization of the mucosal epithelial surface in the chincilla 
nasopharynx [213]. Antibodies against PilA induces the formation of antibodies that eradicate 
NTHi from middle ear fluids and mucosal biofilms of experimental otitis media from the 
chinchilla middle ear [215]. Antibodies directed against P5 have also shown to be protective in 
rat and chinchilla models of middle-ear infection [205]. During chronic infections with NTHi, 
P5 is antigenically variable, potentially permitting the bacteria to evade immune recognition 
and killing [202]. However, this may be overcome by delivering P5- and PilA-targeted 
immunogens together with an adjuvant. This immunisation strategy has been shown to induce 
significantly earlier clearance of NTHi from the nasopharynges and middle ears of chinchillas 
compared to immunogen or adjuvant alone [215].  
 
Carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM-1) 
NTHi and M. catarrhalis are able to utilize CEACAM-1 as a receptor for efficient adhesion, 
and internalisation, and to induce apoptosis and suppression of Toll-like receptor-2 (TLR2) and 
TLR4 as an immune-evasion strategy [216]. The CEACAM family is a group of 12 highly 
glycosylated intercellular adhesion molecules involved in signalling events that mediate key 
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processes including cell adhesion, proliferation and differentiation, as well as tumour 
suppression and apoptosis [217]. CEACAM-1 binding is mediated by P1, an outer membrane 
protein in NTHi, and ubiquitous surface protein A1 (UspA1), an outer membrane protein in M. 
catarrhalis [218]. Both pathogens can increase the expression CEACAM-1 on host cells, 
thereby increasing host susceptibility to bacterial infection [218].  An in vivo study with 
chinchillas reported that anti-CEACAM-1 antibody (YTH71.3) effectively blocked NTHi 
attachment to the nasopharynx [218]. However, a direct correlation between CEACAM-1 
levels and COPD has not yet been found [217]. Despite a lack of correlation, inhibition of 
binding to CEACAM-1 may be effective in preventing infection with NTHi and M. catarrhalis. 
However, studies have also shown that the intrinsic signalling of CEACAM-1 is also essential 
for generating efficient B-cell survival and protective anti-viral antibody response. CEACAM-
1 may function as broad-spectrum antiviral suppressor including influenza virus [219] and the 
absence of CEACAM-1 on B-cells leads to insufficient anti-viral B-cell response in mice [220]. 
Similarly, CEACAM1 is found to be an important regulator of virus-specific CD8+ T cell 
functions in mice and humans [221]. Thus, blocking this pathway may increase susceptibility 
to viral infection. However, a study of mice with altered expression Ceacam1a failed to 
develop clinical signs of viral infection with mouse hepatitis virus, produced smaller viral load 
in the liver and survived a dose 100-fold higher than wild-type mice. This was a result of the 
reduced expression of CEACAM-1a/D1-4 proteins and altering the ratios between two- and 
four- domain CEACAM-1a isoforms in vivo. These results suggest an isoform-dependent 
activity of CEACAM-1, which may be relevant in COPD [222]. 
 
Sialic acid (SA) and Haemagglutinin A (HA-A) 
SAs are a group of nine-carbon monosaccharides that decorate the surface of most mammalian 
cells, mostly in cell membrane glycoproteins. These residues contribute to the functioning of 
several biological systems, including the stabilisation of glycoproteins and cellular membranes, 
and assisting in cell-cell recognition and interactions [223]. There have been reports of 
increased levels of SA in the serum and saliva if COPD patients [224, 225]. Influenza viruses 
primarily infect bronchoepithelial cells (BECs) through the binding of viral HA-A to specific 
host SA–terminated glycoproteins. SAa2,6Gal and SAa2,3Gal residues are mainly found on 
upper and lower respiratory epithelial cells and are preferentially bound by human and avian 
influenza viruses, respectively [31, 226]. Following anchorage to host cells, the influenza virus 
is internalised by endocytosis into the endosome. The low pH environment of the endosome 
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allows the viral HA-A to undergo a conformational change and fuse with the endosomal 
membrane, thereby allowing the release of viral genes into the host cytoplasm [125, 227, 228].  
 
Disruption of viral attachment has been proposed by two main mechanisms. The first is direct 
competition with SA binding by blocking receptor sites of HA-A, either directly with small 
peptide molecules [229, 230] or by neutralising antibodies targeted against HA-A subunits 
[231]. The second strategy involves interference of the HA-A conformational change necessary 
for viral fusion [232-234], thus preventing the subsequent release of viral RNA into host cells 
[235]. Preventing viral replication early in the infection cycle has proved to be a promising 
tactic in preventing and treating viral infections and may provide cross-protection of different 
viral strains [236].  
 
A plethora of entry-blocking peptides are in development that display broad anti-influenza 
virus activity [236, 237]. Of these peptide-based inhibitors, only Arbidol has been approved 
for administration in humans, albeit only in Russia and China [236]. Arbidol has the ability to 
elicit protective broad-spectrum antiviral activity against a number of respiratory viruses such 
as influenza, RSV, HRV, coxsackie virus and adenovirus in vitro and in vivo [152, 238]. By 
functioning as molecular glue, Arbidol stabilizes the prefusion conformation of HA that 
inhibits the large conformational rearrangements associated with membrane fusion in the low 
pH of the endosome [239]. Arbidol has been found to reverse the main symptoms, reduce 
incidence of complications and contribute to the stabilisation of adaptive reactions in patients 
with acute respiratory viral infections [240]. A study of 100 patients with COPD or asthma 
found that seasonal and post-exposure prophylaxis using Arbidol (Umifenovir) was associated 
with 2.6-times reduction in influenza and acute respiratory viral infection related morbidity 
during an epidemic period. This study also showed that prophylactic administration of Arbidol 
before and during flu season reduced the frequency of infectious exacerbations of COPD [241]. 
Although clinical effectiveness has been shown, anticipating adverse events are difficult as 
Arbidol is the only available drug that targets HA-A and the structural information on drug-
HA complexes is limited [239]. Although there are no reports of Arbidol resistance so far, 
[242] drug resistance is still a concern as influenza viruses mutate frequently and unpredictably, 
especially in the HA-A gene [243]. 
 
As an alternative to vaccines, neutralizing monoclonal antibodies (MAbs) represent a passive 
therapeutic strategy to provide immediate protected against influenza virus infection [244]. The 
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MAb, HA-7 was found to potently neutralise and completely protected mice against lethal 
challenges of H5N1 [231]. This MAb specifically targets the highly conserved epitope HA-A 
“head” subunit (HA1), which is mainly responsible for receptor binding [231]. MAb CR6261 
was found to neutralize multiple influenza subtypes by blocking the conformational 
rearrangements associated with membrane fusion. It was also protective from lethal challenge 
of mice from H5N1, and also with H1N1 when administered up to 5 days post-infection [245]. 
MAb CR8020 exhibited neutralizing activity against most group 2 viruses, including H3N2 
and H7N7 [246] and MAbs 5A7 and 46B8 have shown anti-influenza B activity conferring 
protection in mice. [247] Finally, a MAb that recognizes the HA glycoprotein of all 16 subtypes 
and neutralizes both group 1 and group 2 influenza A viruses confers protection to mice and 
ferrets when passively transferred [248]. It is evident that there are a range of MAbs with 
varying subtype binding and/or neutralization spectra which raises the possibility of combining 
different MAbs that could provide broad protection against all seasonal and pandemic influenza 
A viruses [249].  
 
Entry-blocking with small molecule peptides and MAbs both manipulate the HA-A-mediated 
attachment to host SA. However, two HA-A subtypes, H17 and H18 from influenza viruses 
isolated from bats, do not bind to SA and the receptor for these viruses is not yet known [250]. 
This suggests a novel mechanism of influenza A virus attachment and activation of membrane 
fusion for entry into host cells. Thus, bats may constitute a potentially important reservoir for 
influenza viruses [251]. Although it is unlikely, there is the possibility that bat-derived genomes 
could exchange genetic information with human influenza viruses through reassortment, 
resulting in an immunologically unrecognisable influenza strain. The prospect of natural 
reassortment has been realised by the in vitro reassortment of a H1N1 virus with NS1 from the 
bat strain H17N10 that was able to propagate [252]. Furthermore, an infectious bat-derived 
chimeric influenza virus containing HA-A and NA from a human influenza virus was shown 
to replicate well in a broad range of mammalian cell cultures including, human primary airway 
epithelial cells and in mice in-vivo [253].  
 
Host immune defence 
Macrophage function and phenotype  
Macrophages have important roles in host immune defence against bacterial and viral 
pathogens in the lung, and their involvement includes recognition of pathogen components via 
TLRs. Lung macrophages exhibit phenotypic and functional plasticity in order to adapt and 
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respond to a variety of insults [254]. Although oversimplified, macrophages can be crudely 
divided into M1 classically-activated and M2 alternatively-activated subtypes. [255] M1 
macrophages promote Th1-type immunity by producing high levels of pro-inflammatory 
cytokines, such as IL-1β, TNF, and IL-12 induced by exposure to bacterial proteins and IFN-
γ. Lipopeptides from NTHi and S. pneumoniae bind to and activate TLR2 [256], while the 
lipopolysaccharide (LPS) and lipooligosaccharide (LOS) from Gram-negative bacteria bind to 
TLR4; viruses activate TLR3,4,7 and 8 [254]. M1 macrophages have potent bactericidal 
properties but are cytotoxic to host cells due to their production of high levels of reactive 
nitrogen and oxygen species. Thus, their tissue damaging effects must be balanced by M2 
macrophages that are involved in immunomodulation, tissue remodelling and fibrosis, and 
promote macrophage efferocytic function. M2 macrophages secrete anti-inflammatory 
cytokines, including IL-10, TGF-β, CCL18, and CCL22 upon exposure to fungi, 
immunocomplexes, helminths, complement components, apoptotic cells, macrophage colony-
stimulating factors, IL-4, and IL-13 [257]. 
 
Despite significant increases in the total number of airway macrophages in COPD, their 
phagocytosis and elimination of microorganisms and apoptotic cells are impaired, suggesting 
defective functional properties [258]. We have found evidence for a macrophage phenotypic 
switch in COPD airways promoting a shift towards the M1 phenotype in the airway wall but 
towards M2 in the airway lumen compared to normal airways [258]. The divergent 
biological functions of M1 and M2 macrophages is dictated by the dichotomous regulation 
of arginine metabolism [259]. Arginase-1 (upregulated in an M2 environment) was found to 
suppress iNOS activity (M1 inflammatory marker) in the airway wall by competing with the 
common substrate arginine. The suppression of anti-bacterial iNOS activity by increased 
arginase-1 activity, along with its own contribution to collagen-1 formation promotes a pro-
infectious environment along with increased wall thickening [258]. The cause of this 
phenotypic switch is unknown but may be an adaptive response to ongoing insult to the 
COPD airways by cigarette smoke and chronic colonisation/infection with bacteria [254]. 
 
In addition to immune-related aberrations, COPD macrophages also exhibit dysfunctional 
bacterial phagocytosis and uptake of dead and apoptotic cells (efferocytosis) which are 
essential functions in maintaining a healthy lung environment [257, 260, 261]. Impaired 
phagocytic ability of alveolar macrophages has been observed in both COPD patients and 
healthy smokers, compared to control subjects. Phagocytic capacity was greater in COPD 
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patients who had ceased, compared with those continuing to smoke, implicating continuous 
smoking as a key mediator of macrophage dysfunction [262]. Attenuated phagocytosis and 
efferocytosis in combination with a pro-inflammatory environment may promote bacterial 
colonisation and lung tissue damage, which collectively contribute to the progression of COPD.  
   
Specific treatments that manipulate macrophage phenotype, efferocytosis and/or bactericidal 
properties may provide an effective means of clearing the respiratory tract and hasten the 
resolution of inflammation. The efferocytic ability of lung macrophages can be restored with 
phosphodiesterase (PDE) inhibitors, such as aminophylline/theophylline, and by levostatin, 
low-dose oxygen and acute phase reactant α-1 antitrypsin in mouse models [263-265]. Recent 
studies using Roflumilast, a newer PDE-4 inhibitor, revealed alterations in the lung 
macrophage phenotype to a more reparative M2 type [266]. Macrolides and statins have been 
shown to improve AM phagocytosis in vitro but further research is required to determine if 
they can correct defective bacterial phagocytosis in COPD [263, 267].  
 
Manipulation of endogenous pro-resolving mediators including lipoxins, E-series resolvins, 
D-series protectins and maresins may also promote resolution of inflammation in COPD [268]. 
These mediators are derived from polyunsaturated fatty acids and act on distinct receptors to 
promote resolution of neutrophilic inflammation by preventing neutrophil recruitment and 
enhancing the removal of these cells by efferocytosis [269]. The pro-resolving molecule 
annexin A1 is gaining attention as a potential therapeutic target for both its roles in 
inflammation and influenza infection [270, 271].  Roles in monocyte recruitment, enhanced 
clearance of apoptotic cells by macrophages, and macrophage reprogramming toward a 
resolving phenotype, have been described [271]. Annexin A1 is also upregulated during 
influenza infection and enhances viral binding, replication, apoptosis and endosomal 
trafficking of the virus to the nucleus [270]. Annexin A1 deficient mice exhibit a survival 
advantage, and lower viral titres after infection with influenza A virus, accompanied by 
enhanced inflammatory cell infiltration [270]. Recently, it has been observed that serum 
Annexin A1 expression is upregulated in COPD patients and is positively correlated with the 
severity of the disease. The inability of Annexin A1 to resolve the chronic inflammation profile 
of COPD suggests that this resolution pathway is dysfunctional.  Indeed, systemic levels of 
pro-resolving mediators are increased and dysfunctional in other chronic inflammatory 
diseases such as inflammatory bowel disease, preeclampsia, and Alzheimer’s disease [272-
274]. Interestingly, in a separate study with a slightly larger sample size, serum Annexin A1 
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was found to be decreased in COPD compared with healthy non-smokers [275]. However, 
results of both studies agreed that HBE Annexin A1 levels increased in response to CSE 
exposure and that annexin A1 correlated positively with the severity of COPD [275, 276]. The 
discrepancies between these two studies are inexplicable, and the similar methodologies 
suggest a sample-related factor. However, both can agree that Annexin A1 potentially plays a 
role in COPD pathogenesis and more studies are needed to solve this problem and determine 
the true role if there is to be any therapeutic development. As well as inhibiting infectious 
exacerbations, modulation of Annexin A1 or other pro-resolution molecules may be able to 
reduce thickening of the airway wall and arrest disease progression in COPD [277]. Such 
treatments may also be beneficial in other lung diseases such as interstitial pulmonary fibrosis 
(IPF) and cystic fibrosis (CF) where macrophages also exhibit impaired efferocytosis [278]. 
 
Macrophage TLR-mediated response  
Dysregulation of TLR-mediated macrophage responses in COPD airways is also implicated in 
the pathophysiology of the disease. It has been suggested that overactive TLR responses, 
stimulated by chronic bacterial colonisation/infection and cigarette smoke, contributes to 
excessive inflammation and subsequent airway remodelling and lung tissue damage induces 
long-term declines in lung function [279]. Whole tissue explants from patients with COPD 
released higher levels of pro-inflammatory cytokines and chemokines TNF and CCL5 
following activation of viral-associated TLR3, 7 and 8, compared with those from smokers 
[280]. Another study showed that TLR4 followed by TLR2 stimulation of alveolar 
macrophages enhanced cytokine production from COPD patients compared to those from 
smokers [281]. While these studies describe mechanisms of how COPD airways may undergo 
prolonged and excessive inflammatory responses during exacerbations, they fail to explain the 
inability of these responses to clear pathogens. They also compare tissue and macrophages 
from smokers and COPD patients without employing a normal non-smoker control for baseline 
comparison. Contrary to these findings, there is evidence to suggest that alveolar macrophages 
from the airways of chronic smokers and COPD patients exhibit dysfunctional responses to 
TLR stimulation [254]. Studies have shown an impaired ability of COPD alveolar macrophages 
to sense bacterial components via TLR2 and TLR4, a response that was not replicated by TLR3 
stimuli [282]. Smoking-mediated oxidative stress reduces the production of a range of 
cytokines from stimulated and non-stimulated alveolar macrophages compared to those from 
non-smokers, which has been associated with reduced MAPK and NF-κB signalling [282-287]. 
Comparative induction of COPD and non-COPD alveolar macrophages by NTHi antigens, 
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LOS and outer membrane protein (OMP) P6 revealed diminished IL-8, TNF, and IL-1β 
responses of COPD alveolar macrophages [288]. These cytokines are important mediators of 
acute inflammatory responses, with downstream roles in neutrophil recruitment, cell growth 
and tissue remodelling [289, 290]. These findings support a paradigm of defective alveolar 
macrophage responsiveness, the inability of the immune response to clear infections and 
dysfunctional tissue repair in COPD.  
 
Synthetic TLR activators are currently in clinical development for treating asthma, allergies 
and infections but may also be useful in COPD during infectious exacerbations [291]. TLR 
agonists or adjuvant therapy with the ability to correct the dysfunctional TLR-mediated 
responses of COPD macrophages could boost protective inflammatory responses to quickly 
clear pathogens and reduce the oxidative stress in the airway epithelium. Specific TLR agonists 
could be used to induce desirable response, such as a Th1 responses that could lead to 
neutrophilic inflammation, in addition to the suppressive effects on Th2 or regulatory T cells 
[292]. Intranasal delivery of the TLR7 agonist, imiquimod prevented peak viral replication, 
bodyweight loss, airway and pulmonary inflammation, and lung neutrophils in mice following 
influenza A infection. Imiquimod treatment also resulted in a significant reduction in pro-
inflammatory neutrophil chemotactic cytokines and prevented the increase in viral-induced 
lung dysfunction [293]. However, this approach may be difficult to manage as to not amplify 
unwanted inflammatory tissue destruction. Before utilizing such therapies, the exact 
mechanisms surrounding inflammatory signalling pathways in COPD need to be fully 
elucidated. 
 
Oxidative stress 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) produced by immune cells 
exert antimicrobial activity against a broad range of invading pathogens, performing an 
important role in immune defence. However, their excessive accumulation or impaired 
clearance by antioxidant mechanisms results in oxidative tissue damage, including DNA 
damage, lipid peroxidation, and protein denaturation [294-296]. An increase burden of 
oxidative stress is recognised as an important feature in airway tissue damage and pathogenesis 
of COPD as a result of continuous ROS production [296-299]. Despite involvement in driving 
the onset of COPD, cigarette smoke-induced oxidative stress is not resolved after smoking 
cessation [300], implicating other endogenous factors, particularly persistent infection or 
pathogen presence as primary drivers of excessive ROS accumulation [297]. Key COPD 
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pathogens such as Influenza A, RSV and S. pneumoniae have been shown to elicit excessive 
production of oxidative stress markers in mouse models of COPD [298, 301, 302]. Despite the 
defensive role of ROS, their excessive accumulation may have deleterious functional effects 
on AM phagocytosis and efferocytosis, impairing clearance of pathogens, leading to an 
increased ROS response with the inability to clear an infection [303]. Thus, interrupting this 
cumulative cycle of excessive ROS production and impaired bacterial clearance and resolution 
of inflammation may be the key to managing COPD disease progression as well as reducing 
infectious exacerbation risk. Decreasing the excessive oxidative burden in COPD may be 
achieved by either, increasing endogenous antioxidant enzyme activity via enzyme modulators, 
or by inhibiting enzymatic sources of ROS production [296].  
 
The family of NADPH oxidases (NOX) are important enzymatic sources of ROS and while 
they share the capacity to transport electrons across the plasma membrane, family members 
exhibit markedly different activation mechanisms and tissue distribution [304]. Of this family 
the primary source of inflammatory cell ROS is the NOX2 isoform which targets killing of 
bacteria and fungi via phagosomal ROS production [301]. However, there is evidence 
suggesting this elicited ROS response is not protective against and may even promote viral 
infection. In the absence NOX2, influenza A virus causes substantially less lung inflammation, 
injury and dysfunction, and leads to lower viral burden in mice [301, 305]. Conversely, 
prophylactic inhibition of NOX2 activity, ameliorated influenza A virus-induced lung 
inflammation, injury [295] and viral replication in mice [302]. The pivotal role of NOX2 as a 
primary generator of ROS and its potential role in viral-induced exacerbations makes it an 
enticing therapeutic target. However, there is also evidence that potentially implicates NOX2 
in the pathogenesis of COPD. Gene expression of NOX2 is significantly upregulated, and 
associated with airway inflammation in COPD [306]. Similarly, macrophage-specific NOX2 
has been implicated in the pathogenesis of elastase-induced emphysema in mice [307]. Of the 
studied NOX2 inhibitors, the most common is apocynin, which preferentially blocks NOX2 by 
preventing assembly of enzyme subunits [308]. Studies in mice models of COPD have shown 
that in vivo administration of apocynin significantly suppresses viral titre, airway inflammation 
and cell superoxide production following viral infection [298, 301] and exposure to cigarette 
smoke [296]. Clinically, COPD patients treated with apocynin exhibited reduced H2O2 and 
NO2
− in their exhaled breath concentrate compared to placebo control [296]. However, there 
are also concerns about the possible immunosuppressive side effect of NOX2 inhibitors, that 
may contribute to increased infection and/or autoimmune disorders [309]. Although infection-
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related symptoms are only seen when the NOX activity is <15–20% of normal in otherwise 
healthy individuals, [310] it may be difficult to predict a therapeutic threshold in COPD which 
displays a multifaceted susceptibility to infections. Although NOX2 has taken the spotlight, a 
study examining the NOX expression in COPD bronchial brushings has highlighted the 
importance of the different NOX family isoforms [306]. Of note, gene expression of NOX4 
and dual oxidase 2 (DUOX2) were increased and NOX1 was decreased compared to normal 
controls. Multiple regression analyses also identified independent associations between: NOX1 
and DUOX2 with airflow obstruction; NOX1 with airway inflammation (neutrophils and 
eosinophils) [306]. NOX4 may also be involved in promoting airway smooth muscle 
remodelling in the small airways of COPD [311, 312] and is readily induced by cigarette smoke 
[307]. Thus, isoform differences may impact effectiveness of new therapies targeting NOX-
generated ROS, particularly as drugs like apocynin are isoform-specific [308].  
 
Alternatively, increasing antioxidant capacity in COPD has been proposed via manipulation of 
the glutathione peroxidase (Gpx) family of enzymes or superoxide dismutase (SOD). These 
enzymes are work in tandem to inactivate superoxide produced by cellular respiration and 
enzymatic ROS generators such as NOX [313, 314]. SOD3 is a major extracellular antioxidant 
enzyme that is highly expressed in lungs and accounts for the majority of SOD activity in 
airways and vessels [315]. SOD3 plays a major role in the formation of H2O2 by dismutation 
of superoxide, while the he Gpx family of enzymes, along with catalase, are responsible for the 
termination of the ROS cascade primarily by reduction of this H2O2 to H2O and O2 [314].  Of 
the known eight isoforms, Gpx1 is the predominant isoform of cellular Gpx and is ubiquitously 
expressed throughout the body, including lung epithelium, alveolar epithelial lining fluid and 
alveolar macrophages [294]. Gpx and SOD3 levels are overexpressed in erythrocytes  and 
sputum, respectively in both COPD and smokers [316, 317]. However, the inability of these 
antioxidants to resolve oxidative burden suggests an overwhelmed or dysfunctional antioxidant 
capacity. Multiple classes of SOD or Gpx mimetics have been developed and have generally 
demonstrated effectiveness in animal models of COPD but are yet to be translated into humans. 
Mice lacking the gpx-1 gene were highly susceptible to oxidative stress [294, 299] and 
administration of the Gpx mimetic ebselen,  or a SOD mimetic, significantly inhibited cigarette 
smoke-induced lung inflammation when given prophylactically and during established 
inflammation [294, 296, 299]. Ebselen caused a reduction in influenza A virus-induced lung 
inflammation [318] and mice with selective overexpression of extracellular SOD displayed 
significantly less lung injury from influenza virus [313]. This suggests that Gpx-1 or SOD 
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mimetics may have therapeutic utility in preventing viral-induced AECOPD. These antioxidant 
enzymes have also shown in vivo efficacy in protecting against diseases hallmarked by 
oxidative stress such as emphysema [299, 319], whereas Gpx-1 knockout mice exhibited an 
exaggerated emphysema phenotype [299]. Several genetic studies have identified an 
association between SOD3 polymorphisms and altered risk of COPD. A mutation associated 
with hyper-production of SOD3 was protective against development of COPD among smokers, 
but not in non-smokers [320]. A different pair of polymorphisms was also associated with 
reduced lung function in COPD patients compared to normal population [315].  
 
While inhibiting ROS-production or enhancing ROS-resolution shows potential clinical utility 
in preventing viral-induced exacerbations and disease progression of COPD, there is limited 
research regarding their efficacy and safety in humans. Elucidating mechanism by which ROS 
production paradoxically promotes virus pathogenicity and COPD pathogenesis will allow 
development of a multifaceted therapy.   
 
 
 
 
Respiratory Microbiome  
The role of a beneficial, healthy bacterial microbiota is well established in the gastrointestinal 
tract, where resident bacteria aid in establishing a balanced immunological phenotype, compete 
with potentially harmful micro-organisms and synthesize a variety of beneficial biomolecules 
[321]. The respiratory system was initially thought to be a sterile environment but novel 
culture-independent techniques of microbial identification have since revealed the previously 
unappreciated complexity to the respiratory microbiome [322]. Recent research has made it 
evident that a variety of chronic lung disorders, including asthma, COPD, and cystic fibrosis, 
are strongly linked to airway dysbiosis, generally accompanied by a loss in bacterial diversity 
due to the outgrowth of certain pathogenic bacteria [323, 324]. Bacterial composition of the 
bronchial microbiome remains relatively stable in clinically stable COPD but exhibits 
overrepresentation of COPD-associated bacteria such as Haemophilus, Moraxella, and 
Neisseria during an exacerbation [325-329]. Potentially pathogenic members of the 
Pseudomonadaceae, Enterobacteriaceae, and Helicobacteraceae families, not typically 
associated with COPD, were also isolated from COPD patients experiencing severe 
exacerbations [330] and strongly correlated with presence of Haemophilus influenzae [325, 
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326]. These correlative relationships across Proteobacteria members suggests that pathogenesis 
of exacerbations could involve a polymicrobial process. COPD airways have also been found 
to be enriched with oral taxa associated with subclinical lung inflammation, such as 
Prevotella and Veillonella [331], as well as gut-associated species [330]. These findings 
suggest that the URT and gastrointestinal tract may act as a microbial reservoir for seeding the 
airways in COPD, and provide an association between a distinct human microbiome and 
inflammation in the lung [331, 332]. COPD airways also exhibit a decreased abundance of 
other bacteria whose predicted metagenomes suggest functional capacities to produce a variety 
of anti-inflammatory compounds [325]. 
 
Given that carriage is prerequisite for the development of disease, maintaining balance of the 
upper respiratory tract (URT) microbiome is vital in maintaining respiratory health. 
Introduction of bacteria to the lower respiratory tract (LRT) occurs through physiological 
episodes of micro-aspiration [333]. The importance of oral health and micro-aspiration was 
highlighted by a study in residents of nursing homes, showing that neglect of oral health 
measures leads to a dramatic increase in incidence of and mortality by pneumonia [334]. 
Likewise, absence of MRSA carriage in the nasopharynx negatively predicted a lower 
respiratory tract infection caused by the organism, with a negative predictive value of 98.5% 
[335]. Strong evidence suggests that a healthy URT microbiome infers colonisation resistance 
by preventing acquisition and establishment of a new pathogens, or by containment of 
potentially pathogenic bacteria residing amidst harmless commensals [336]. Although potential 
pathogens such as NTHi and S. pneumoniae comprise the normal URT flora, a state of bacterial 
symbiosis may be protective against short-term infection and inflammation [329]. However, 
natural microbiome and immune defences against overgrowth of a potential pathogen are 
susceptible to malfunction following acquisition of a new bacterium or viral co-infection [329]. 
This resultant state of temporary dysbiosis in the absence of adaptive immunity may be 
resolved by administration of a probiotic that can diminish pathogen colonisation either by 
direct competition or indirect stimulation of innate and adaptive immunity [336].  
 
Immune modulation  
Viral and bacterial pathogens have a complex and potentially synergistic relationship in the 
respiratory tract. Viral infection, particularly with HRV, RSV or influenza results in enhanced 
growth of pathogenic bacteria, mainly of the Proteobacteria phylum (e.g., H. influenzae and 
Moraxella), which could explain the predisposition to secondary bacterial infections in COPD 
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[323]. Several studies have also reported a persistent presence of potentially pathogenic 
microbes in the LRT of individuals with COPD coinciding with a reduction in microbe 
diversity [328, 332, 337]. Conversely, presence of potentially pathogenic bacteria is predictive 
of RSV bronchiolitis in children and in some cases could be linked to severity of the infection 
[338]. TLR3 expression, and consequently recognition of viral structures and antiviral type 
I/III IFN production, was shown to be impaired in bronchial epithelial cells exposed to 
Moraxella catarrhalis [338]. Thus, a healthy respiratory microbiome may also aid in limiting 
risk and severity of viral infections as well as the tissue damage following excessive 
inflammation induced by viral infection [321]. Colonization of the URT with commensal 
bacteria has been shown to drastically reduce influenza-induced acute lung injury and mortality 
in mice [339, 340]. Microbiome modulation was more effective in preventing virus induced 
hyperreactivity than pre-treatment with synthetic TLR agonists [341]. An intact microbiome 
has also been shown to be required for the formation of an adaptive response against influenza 
virus in mice [342].  
 
These protective benefits have been implicated with probiotics regulating monocyte 
recruitment, production of anti and proinflammatory cytokines, and balance between types of 
T cell responses such as Th1/Th2, Treg, and Th17 responses [340, 343]. It has also been 
proposed that the protective effects of probiotics (both intranasal and oral) are also associated 
with stimulation of NK cell function including production of IFN-γ, as well as induction of M2 
macrophages within the airway mucosa  [343]. NK cell activity and cytokine release is 
critically important to the early control of viral infection but is impaired in smokers [343], and 
in COPD [344-346]. 
 
Direct competition  
The battle for similar nutrients and the bacterial secretion of antimicrobials provide a direct 
means of competition between beneficial and harmful microbes [336]. For commensals and 
pathogens living in or invading human tissues, iron is often a limiting nutrient, particularly in 
the respiratory tract where iron concentrations are considered to be low [347]. In bacteria, iron 
is a co-factor for many enzymes and plays a crucial role in diverse physiological processes 
such as DNA replication, transcription and central metabolism [348]. The primary iron source 
for bacteria is haem, protoporphyrin IX (ppIX) that contains an iron ion at its centre [349]. The 
entire haem molecule is also essential to the function of haemoproteins, which are involved in 
energy generation by the electron transport chain, detoxification of host immune effectors and 
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other vital processes [349]. To restrict microbial growth, free haem and iron are tightly 
regulated by the host and is sequestered in high-affinity haemoproteins or macrophages, 
respectively [348, 350]. Iron-regulatory responses differ between macrophage phenotypes: M1 
cells accumulate iron as part of a bacteriostatic stratagem linked to the anaemia of chronic 
inflammation, whereas the opposite is the case for M2 cells, where iron release is favoured 
[347]. 
 
Indirect evidence provides insight whereby increased iron levels in the lungs of smokers, 
COPD or CF patients may contribute to the increased susceptibility to airway infections [351]. 
A rat study showed that airway iron was elevated after exposure to cigarette smoke, leading to 
increased tissue-damaging oxidative stress and release of IL-8 [352]. An increase in IL-8 may 
contribute to the increased susceptibility to viral infection via activation of EGFR [353-355]. 
Increased iron levels in COPD lung occurs as a result of genetic dysregulation of iron 
regulatory protein (IRP2) and deposition of inhaled iron from cigarette smoke [356]. The iron 
status of the host is very important in determining the risk of pulmonary infection. For example, 
correction of iron deficiency led to activation of previously suppressed, pre-existing infections 
including malaria, brucellosis and tuberculosis, in a group of Somali nomads [356]. As iron 
repletion advanced, infectious activity reached a peak, showing that iron repletion can also 
allow infectious diseases to become more clinically overt [356].  
 
Given the role of iron in the pathophysiology and increased susceptibility to infection in COPD 
lungs, inhaled iron chelators may be a potential therapeutic approach to AECOPD [347]. 
Intracellular iron chelators such as deferiprone, which specifically target intracellular iron 
deposits and relocate them outside the cell to prevent cellular iron loading [357, 358] may have 
more therapeutic efficacy than regular cell-impermeable iron chelators such as deferoxamine 
[359]. A surgical wound-gel loaded with the iron chelator deferiprone and the heme-analogue 
gallium-protoporphyrin showed significant antibiofilm activity against multi-drug resistant 
Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa and 
Acinetobacter johnsonii. The gel also potentiated the antibacterial activity of ciprofloxacin 
against these organisms [358]. This study provides a “proof of principle” for the efficacy of 
therapies that take advantage of bacterial nutritional requirements and may be useful in the 
inhibition on diverse bacterial species. However, applying this concept to an inhaled 
preparation would require further studies that assess the effects of using inhaled iron chelators 
on systemic iron metabolism. [347] 
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NTHi is uniquely susceptible to haem restriction as, unlike most bacteria, it cannot make its 
own and relies solely on haem acquisition from the host [349, 360, 361]. As such, expression 
of haem-acquisition genes in NTHi is an important determinant of survival and modulation of 
virulence factors, which is highlighted by the increased prevalence of these genes in middle 
ear strains than colonising throat strains [362]. Deletion of multiple genes related to haem-iron 
scavenging, utilisation and regulation have resulted in the attenuation these virulence factors 
and disease severity and duration in animal models of otitis media [350, 361, 363]. Similarly, 
an isogenic mutant of two haem-acquisition pathways was unable to sustain bacteraemia or 
produce meningitis in a rat model of invasive disease [364]. Thus, haem-acquisition pathways 
represent potentially high value targets for the development of novel therapies for the 
eradication NTHi from the respiratory tract, particularly in COPD [365, 366]. Alternatively, a 
probiotic approach that takes advantage of NTHi’s reliance on haem-acquisition has been 
proposed. Haemophilus hameolyticus (Hh) is considered a respiratory commensal and recent 
observations support the bacterium as a potential probiotic candidate against NTHi colonisation 
and infection [367]. In an in vitro cell culture model of human lung epithelium, pre-treatment 
with Hh significantly inhibited colonisation and transcytosis of NTHi to cell monolayers [6]. 
A bacteriocin-like substance produced by a minority of Hh strains was isolated with the ability 
to inhibit NTHi growth in vitro. The inhibitory mechanism of this substance has not been fully 
elucidated but ongoing research indicates the inhibitory effect of this NIS is due to its capacity 
to bind haem, thus limiting its access to NTHi [368]. Eradication of NTHi carriage from the 
nasopharynx and subsequent migration to the lower airways would be an effective means of 
preventing infection with the organism. However, further research is required to investigate the 
inhibitory effect of this substance in cell culture models and implications on co-colonisation of 
the shared nasopharyngeal niche. 
 
 
Immune signalling pathways   
Multiple kinases play a critical role in modulating inflammation and downstream antiviral 
immune responses [369, 370]. However, respiratory viruses possess numerous mechanisms of 
subverting these responses to facilitate viral entry into host cells and replication. Kinases are 
an enticing therapeutic target but must overcome developmental hurdles, such as specificity 
and off-target effects, before implementation as effective preventive therapy for viral-induced 
AECOPD [369, 370]. 
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Protein kinase C (PKC) 
The protein kinase C (PKC) superfamily is linked to several downstream signalling pathways 
and is therefore responsible for diverse regulatory roles in membrane structure events, immune 
responses, gene transcription and cell growth [371]. The influenza virus and the viral HA can 
rapidly activate PKCs upon binding to host-cell surface receptors [138]. In vitro experiments 
show that host cell entry and infectivity of several enveloped viruses, including influenza A 
and B, could be inhibited by PKC inhibitors, implicating the critical involvement of PKCs 
critical the enveloped viral entry process [372, 373]. Although the full mechanism of PKC-
mediated viral entry has not been elucidated, the PKCbII isoform has been implicated as an 
important regulator of late endosomal sorting events needed for influenza virus entry and 
infection [138, 374]. In vitro kinase activity assays of infected A549 cells showed that RSV 
infection also resulted in the upregulation of multiple PKC isoforms with subsequent 
downstream activation of extracellular signal-regulated kinases. The RSV-mediated 
upregulation of PKC activation was implicated in the host cell fusion process, a pivotal step in 
inducing a successful infection [371]. Blocking of PKC was also found to significantly impair 
RSV infection of NHBE cells when the inhibitory agent was administered at the onset of 
infection [375]. 
 
These observations suggest pharmacological interference of PKC might help to prevent 
influenza and RSV infections during initial entry of virions into their target cells [138]. One 
approach to interference is the use of defensins. Defensins are antimicrobial peptides of 
polymorphonuclear neutrophils and other leukocytes that are important effectors of the innate 
immune system and have been shown to inhibit a variety of bacteria and fungi [376]. Recent 
evidence also suggests alpha defensins can modulate viral infection with both enveloped and 
nonenveloped viruses, including influenza [237, 377] via inhibition of PKC activation [377]. 
Beta-defensin has also been shown to act as an antiviral molecule against RSV [378]. 
Treatment of cell cultures with alpha-defensin soon after infection resulted in marked inhibition 
of influenza virus replication and viral protein synthesis. Additionally, treatment of cells with 
alpha-defensin followed by its removal before infection also inhibited viral replication, 
suggesting an effective prophylactic approach [377]. However defensin-mediated inhibition of 
PKC would have little effectiveness during an active infection as inhibitory activity is only 
effective when administered during the first 60 minutes of viral infection [373].  
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Regardless of the naturally occurring in vitro antiviral effects of defensins, humans still 
become infected, suggesting that baseline defensin levels are not sufficient to fully protect the 
host from viral infections. Prophylactic overexpression of defensins in mice were protective 
against a lethal influenza A infection and a reduction of the viral lung titre was observed [379]. 
However, more studies are needed to determine if this strategy can be translated to preventing 
viral infection in COPD. [376] Basal alpha-defensin was found to be elevated in COPD and 
further increased post infection with HRV but did not correlate to any changes in viral load 
[380-382]. Additionally, exposure of pBECs to CSE decreased alpha-defensin 1 production in 
healthy controls but remained unchanged in pBECs from COPD patients. [380] Basal beta-
defensin 2 levels have been described in very low titres in COPD central airways ,but not in 
distal airways, and are not affected by viral infections [380, 383]. These results suggest a 
variable role of defensins which is dependent on type and may point toward dysregulation or 
dysfunction of defensins in COPD. Long-term increases in defensin levels carry safety 
concerns as high concentrations of human alpha defensin have been found to induce 
cytotoxicity in vitro [384]. Additionally, higher expression of beta-defensin genes can be 
associated with diseases such as psoriasis [385], and human defensins have also  been shown 
to have effects on tumour microenvironment by either promoting or supressing tumour growth 
[386]. There is also a potential that defensins may enhance certain viral infections, while 
inhibiting others. For example, human alpha-defensin 5 and 6 were shown to increase HIV 
infectivity by enhancing attachment by concentrating virus particles on the target cells [387]. 
 
The plant polyphenol, Resveratrol (RV), is an antiviral compound with a broad-spectrum of 
antiviral activity against DNA and RNA viruses, including HRV and influenza A [130, 388]. 
The antiviral effects of RV are elicited by interfering with several intracellular signalling 
pathways, including PKC and its dependent pathways [136, 389]. In in vivo studies, RV also 
improved survival and decreased pulmonary viral titres in influenza virus–infected mice [136]. 
When administered in the form of a nasal spray, RV was found to be safe and effective in 
reducing the severity and recurrence of respiratory infections in children [130, 388].  
 
Protein kinase R (PKR) and viral non-structural (NS1) protein 
The presence and replication of viral nucleic acids in vertebrate cells triggers a potent antiviral 
innate immune response, in particular the induction of type-I IFN genes and the activation of 
viral enzymes [390]. The double-stranded RNA-dependent PKR is a key executor of this 
antiviral response, along with other IFN-stimulated gene products [390]. As a defence against 
35 
 
this antiviral response, influenza viruses express a multifunctional NS1 protein with the major 
function being to counteract or prevent the PKR-mediated antiviral response [391, 392]. NS1 
protein can prevent PKR detection by binding to viral RNA [393, 394] or, by direct binding, 
can inhibit PKR-mediated viral mRNA suppression and induction of apoptosis. Additionally, 
some strains are able to directly inhibit the expression of IFN [395, 396]. NS1 not only mediates 
antiviral suppression but also modulates other important aspects of the virus replication cycle, 
which may additionally contribute towards efficient virus replication and virulence during 
infection [397]. Additional roles of NS1 include viral RNA replication, viral protein synthesis, 
and general host-cell physiology [125, 390, 392].  
 
Given the numerous roles during virus replication, antiviral compounds that inhibit NS1-
actived signalling cascades or augmentation of IFN antiviral pathways could be a promising 
preventative strategy against influenza infection in COPD. Influenza A virus mutants unable 
to express NS1 (delNS1), or that possess a truncated form of NS1, induce high levels of IFN 
in infected cells, and are consequently attenuated in IFN- α/β-competent systems [398, 399]. 
Inhibition of IFN pre-mRNA was found to be mediated by the binding of viral NS1 to cellular 
CPSF30, thus indicating this interaction as a potential therapeutic target [400]. Peptide-
mediated inhibition of NS1-CPSF30 binding has been shown to limit virus replication in tissue 
culture [399, 401, 402]. However, this strategy is specific to influenza A and is yet to be tested 
in vivo [399]. Recombinant influenza viruses with truncated or mutated NS1 proteins have also 
been investigated for their potential as live-attenuated vaccine candidates [392]. Such viruses 
are partially debilitated in their ability to counteract the host IFN response, but retain 
immunogenicity and replicative ability, making them an ideal vaccine candidate [392, 403, 
404]. NS1-truncated viruses are generally attenuated, except in cells lacking the ability to 
produce appropriate levels of IFN [398, 399]. There is evidence of deficient IFN-induction in 
COPD cells ex vivo, and COPD mice [403, 405]. Therefore, further studies are required to 
properly assess the safety of this approach in COPD, perhaps with the consideration of 
administering recombinant interferon in combination with vaccination. The type- and strain-
specific IFN-antagonistic and binding properties of NS1 [392, 406, 407] may also complicate 
development of therapies that target NS1. Influenza H5N1 encodes an NS1 protein that is 
highly effective in inhibiting host antiviral responses that contributes to it high fatality in 
humans [408, 409]. Transfected NS1 of a human H3N2 strain was also found to be more 
effective in supressing IFN-mediated antiviral response than that of a low pathogenic avian 
influenza, H11N9, which resulted in a higher replication rate [410].  
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An alternative approach is augmentation of the IFN response. Mice lacking functional IFN-λ 
receptors are unable to restrict virus dissemination from the upper airways to the lungs and 
transmit the virus much more efficiently to naïve contacts compared with wild-type mice [411]. 
Prophylactic intranasal treatment with IFN-α inhibited initial virus replication in mice, ferrets, 
guinea pigs or rhesus macaques infected with influenza A [412-414]. However, IFN-α was only 
effective in protecting ferrets from seasonal influenza viruses, which replicate mainly in the 
upper respiratory tract, but not from highly pathogenic influenza viruses, which also 
disseminate to the lung [412]. However, only IFN-λ conferred long-lasting antiviral protection 
in the upper airways and blocked virus transmission in mice [411]. IFN pre-treatment reduced 
viral replication in COPD pBECs exposed to HRV, suggesting a broad-spectrum antiviral 
potential of IFN treatment [415]. Intranasal recombinant IFN-α2b (SNG001) was shown to be 
an effective prophylactic treatment against HRV and prevented exacerbations in asthmatics. 
However, stage 2 clinical trials are yet to reveal any efficacy in preventing viral-induced  
AECOPD  [416]. Another promising avenue is the family of interferon-inducible 
transmembrane IFITM proteins that mediate IFN’s broad-spectrum antiviral role against 
influenza A virus, West Nile virus and dengue virus. IFITM 1, 2 and 3 restricted early steps in 
influenza A infection, and there are no reports of viral escape from IFITM restriction [417-
419]. Evidence also suggests that Ifitm3−/− mice are more susceptible to RSV infection than 
their wild-type littermates. However, RSV restriction has not been examined in cultured cells, 
and it is possible that IFITM proteins protect mice from RSV challenge via means other than 
inhibition of viral entry [419]. IFITM expression has also been shown to influence the quality 
of the adaptive immune response to influenza A virus in mice [419].  
 
Augmentation of the antiviral IFN response appears to be an effective prophylactic strategy in 
animal studies but more trials are required to determine if this effect is translatable to humans 
and whether there is any benefit in preventing AECOPD. The inability of exogenous IFN-β to 
fully restore antiviral responses in COPD pBECs, indicates a partially dysfunctional IFN-β-
mediated signalling in COPD [31]. Thus, simply artificially increasing IFN levels in COPD 
airways may not be sufficient to mount an appropriate antiviral response. It is also not clear 
how augmentation of such a vital host immune response would affect uninfected tissue [392]. 
Mice studies have shown that excessive IFNαβ signalling in response to acute influenza 
infection can result in uncontrolled inflammation leading to lung damage and increased 
morbidity and mortality [420]. Additionally, it causes increased expression of IFN-γ 
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suppressed innate protection against extracellular bacterial pathogens in the lung [421]. This 
may have serious implications for bacteria-induced exacerbations in COPD.  
 
P13K-p110a signalling pathway 
Influenza A NS1 protein is also responsible for the activation of the phosphoinositide 3-kinase 
(PI3K) and the downstream effector protein kinase Akt by direct interaction with the p85 
subunit of PI3K [422, 423]. The normal physiological role of PI3K is in various host cell 
functions such as anti-apoptosis, cell proliferation, growth, metabolism and cytokine 
production/signalling [125, 392]. However, several studies have implicated PI3K in supporting 
efficient virus propagation. Blocking of the PI3K/Akt pathway results in the inability of 
influenza to endocytose into AECs [424], a reduction in virus yield, suppression of viral RNA 
and protein synthesis, and suppression of premature apoptosis at later stages of infection [422, 
423, 425-427]. The role of influenza-induced PI3K activation appears to be dependent on virus 
type. PI3K is activated and regulates early stages of viral entry upon infection with influenza 
B viruses as opposed to the post-entry events at later stages of infection with influenza A [422]. 
Although initial viral replication is dependent on PI3K activation, influenza virus produces 
NS1, which further activates PI3K to further amplify replication [31, 428]. Influenza viruses 
containing a truncated NS1 failed to activate the PI3K/Akt pathway, grew slower and formed 
small plaques in tissue culture [429]. The truncated NS1 protein also conferred an attenuated 
phenotype due to its inability to inhibit host antiviral responses [430].  
 
Hyperexpression of PI3K in lungs of COPD patients has been described, not only providing a 
mechanism of increased viral susceptibility but also may be linked to pathogenesis of the 
disease [431]. Increased expression of PI3K and decreased expression of a negative regulator 
of PI3K (PTEN) correlated with more severe airflow obstruction, regardless of disease stage 
[431]. In primary bronchial epithelial cells and BEAS-2B cells, CSE decreased PTEN protein, 
and PTEN knockdown potentiated Akt phosphorylation and enhanced production of 
proinflammatory cytokines [432]. Exaggerated PI3K response has also been described in 
COPD pBECs, which conferred increased susceptibility to influenza infection. Smoke exposed 
mice also supported increased influenza viral replication and produced deficient antiviral 
responses, with exacerbated inflammation and impaired lung function [31]. PI3K-p110α was 
identified as the predominant isoform hyper-expressed in COPD pBECs. Specific inhibition of 
this isoform prior to infection attenuated influenza infection and enhances IFN-β antiviral 
responses in COPD, as well as healthy pBECs [31]. Identification of offending isoforms is 
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beneficial to developing more specific inhibitors and limit off-target activity. The PI3Ky 
subunit has also been shown to have a critical role in the clearance of viral infection [433]. 
PI3Ky is a more specific target as it is only expressed on cells of haemopoietic origin as 
opposed to p100α which is expressed on all cells [434], however PI3Ky has not yet been 
characterised in COPD.  
 
Epidermal Growth Factor Receptor (EGFR) 
EGFR is a receptor kinase which is well known to play an important role in the regeneration 
of damaged tissue, mucin production and elastase-induced IL-8 production in lung epithelial 
cells [353, 435, 436] IL-8 production is particularly important in the context of COPD as 
concentrations are increased during an exacerbation or in patients that experience frequent 
exacerbations [437, 438]. EGFR has been shown to promote influenza A infection of host cells 
either directly or indirectly through activation of PI3K/Akt signalling [354]. Influenza virus 
and HRV induce upregulation of ligands that further activate EGFR and IL-8 production in 
bronchial epithelial cells in vitro, further facilitating viral attachment to airway epithelium 
[353, 355]. EGFR inhibition has been shown to completely block IL-8 and the EGFR ligand, 
ICAM-1, expression to basal levels during HRV infection [355]. Furthermore, aberrant EGFR 
activity has also been described in COPD which subsequently increases PI3K/Akt signalling 
and IL-8 secretion [439], the effect of which is exacerbated by long-term smoking [440, 441]. 
Persistent activation of EGFR by viral infection or through a defect in glutathione secretion in 
COPD may contribute to airway remodelling, an important driver of airway lumen obstruction 
[442-444]. EGFR has also been shown to have an indirect role in the IFN-mediated antiviral 
response. Activation by influenza A virus and HRV suppressed IFN-γ production and increased 
viral replication in BEAS-2B cells [445]. Inhibition of EGFR in mice during viral infection 
augmented IFN- γ production, which resulted in decreased viral titres in vitro and in vivo [445]. 
M. cattarrhalis, another common precipitant of COPD exacerbation, has also been shown to 
activate EGFR. [446] This evidence suggests that inhibition of EGFR may be a multifaceted 
therapeutic approach with the potential to not only prevent bacterial and viral-induced 
exacerbations, but also affect the overall pathophysiology of COPD.    
 
Strategies developed for antagonising EGFR signalling include MAbs that prevent endogenous 
ligand engagement, [447, 448] or small molecule inhibitors which target specific downstream 
EGFR signalling pathway components [369]. However, research in MAbs has primarily 
focused on treatments for lung cancer and have not yet been contextualised for COPD [369]. 
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Suppressor of cytokine signalling (SOCS) protein regulation of EGFR has shown a pivotal role 
in restricting influenza A virus in airway epithelium. Socs5-deficient mice exhibit heightened 
disease severity, with increased viral titres and weight loss [32, 449]. In COPD airway 
epithelial cells, Socs5 was found to be downregulated, which correlated with increased 
susceptibility to influenza infection. Importantly, restoration of SOCS5 levels restricted 
influenza virus infection, suggesting that manipulating SOCS5 expression and/or SOCS5 
targets might be a novel therapeutic approach to influenza [32]. Fucoidan, an algae-derived 
sulphated polysaccharide has also exhibited broad anti-influenza activity in mice by enhancing 
the immune response [450] and blocking EGFR-mediated viral entry [354, 451]. Studies 
assessing the therapeutic potential of fucoidan in humans is limited but reveals an additional 
immune-modulatory role that may increase vaccine efficacy in immunocompromised 
individuals. Elderly participants treated with Mekabu fucoidan produced higher antibody titres 
and exhibited an increase in natural killer activity against influenza strains in a seasonal 
influenza vaccine [450]. Further studies are required to assess these effects in COPD.  
 
CONCLUSIONS 
Infectious exacerbations are a primary driver of clinical and functional decline in COPD, but 
existing therapies are of limited effectiveness and do not effect the overall course of the disease. 
The rapid development of antibiotic resistance and microbial evasion of vaccination strategies 
further complicates the treatment and prevention of these infections. In order to mount an 
infection, a pathogen must exploit host-cell surface receptors for attachment and evade 
clearance by host immune responses. Therefore, novel therapeutic strategies that disrupt 
bacterial-host cell interactions or that mediate the host inflammatory response present an 
attractive approach to reducing infectious exacerbations in COPD. The usefulness of pathogen 
proteins as vaccine candidates are limited by antigenic variation, thus targeting specific host 
receptors may be a more promising approach. Modulation of the aberrant inflammatory 
response in COPD by altering immune cell function, signalling pathways, balancing the 
microbiome or reducing oxidative burden may have added utility of affecting disease 
progression as well as preventing infectious exacerbations. However, due to integrated nature 
and complexity of the immune response, a combination of approaches may be required to elicit 
any benefits. These strategies are less likely to induce antimicrobial resistance as a missing 
cellular function is more difficult for a pathogen to adapt to, and should affect replication 
independent of the type, strain and antigenic properties of the invading pathogen. However, 
host-targeted approaches may be more complex to manage due to the increased concern of off-
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target side effects, and their development may be hindered by the uncertainty surrounding the 
mechanisms of COPD pathogenesis. It is imperative that the mechanisms driving COPD 
pathogenesis be resolved, which will facilitate the development of effective treatment 
strategies. Further development of such preventative strategies has the potential to significantly 
reduce AECOPD, prevent disease progression and associated mortality and economic costs, as 
well as improving health-related quality of life for affected individuals. 
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Figure 1. New potential therapies targeting pathogen-host binding and immune signalling 
pathways involved in infectious exacerbations of COPD. Bacterial and viral pathogens 
inhaled from the upper respiratory tract or the environment exploit upregulated host cell 
receptors for attachment via their cognate ligands. Pathogen adhesion to host receptors causes 
further upregulation of some host receptors which facilitates chronic colonization and invasion 
of COPD airways. Epithelial binding triggers immune defences which are mitigated by the 
invading pathogen at various steps in the immune signalling pathway. Avoidance of immune 
clearance by a dysfunctional immune response allows pathogens to further facilitate chronic 
colonisation and cause acute exacerbations that contribute to progression of COPD. The 
additive effects of macrophage dysfunction, pathogen persistence and oxidative stress also 
contribute to disease progression through thickening of the airway wall. Potential therapeutic 
agents/inhibitors of pathogen host-cell attachment and the altered immune response are 
demonstrated in orange.  NTHi, nontypeable Haemophilus influeanzae; RSV, respiratory 
syncytial virus; HRV, human rhinovirus; ChoP, phosphorylcholine; gG, glycoprotein G; gF, 
glycoprotein F; HA, haemagglutinin; OMP, outer membrane protein; UspA1, ubiquitous 
surface protein A1; EBP, entry-blocking peptide; Mab, monoclonal neutralising antibody; 
CEACAM, anti-carcinoembryonic antigen cell adhesion molecule 1; ICAM-1, Intracellular 
adhesion molecule 1; PAFR, platelet-activating factor receptor; GAG, glycosaminoglycan; SA, 
sialic acid; RV, resveratrol; NS1, non-structural protein; IFN, interferon; IFITM, interferon-
inducible transmembrane; PTEN, Phosphatase and tensin homolog; PI3K, phosphoinositide 3-
kinase; SOCS, suppressor of cytokine signalling; PKC, protein kinase C; PKR, protein kinase 
R; EGFR, epidermal Growth Factor receptor; TLR, toll-lik receptor; PDE, Phosphodiesterase; 
COPD, chronic obstructive pulmonary disease; IL-8, interleukin 8. 
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Table 1: Current therapies and clinical trials in COPD 
Reference 
Drug names/ 
combinations and 
target 
COPD 
condition 
and stage 
Clinical 
trial 
(Phase) 
Study details 
and patient 
numbers 
 
Outcomes and 
conclusions 
Triple versus dual therapies with combination of inhaled corticosteroids, LABA and LAMA 
Halpin 
et al  
FULFIL 
study        
[452] 
Once daily triple 
therapy 
(ICS+LABA+LAMA) 
fluticasone 
furoate/umeclidinium/vi
lanterol compared to 
twice-daily dual therapy 
(ICS+LABA) 
budesonide/formoterol 
Moderate 
to severe 
Phase III 
clinical 
trials 
A total of 2240 
patients 
participated 
and were sub-
grouped. 1121 
patients 
received triple 
therapy while 
1119 received 
dual therapy 
Once daily triple 
therapy showed 
reductions in 
moderate- severe 
exacerbation rates 
compared with twice-
daily dual therapy. 
The effectiveness of 
the therapy was 
regardless of disease 
severity or 
exacerbation history 
or prior COPD 
medication 
Lipson et 
al  
IMPACT 
study 
[88] 
Once daily triple 
therapy 
(ICS+LABA+LAMA) 
fluticasone furoate 
umeclidinium/vilanterol 
compared to fluticasone 
dual therapy (ICS + 
ultra LABA) furoate–
vilanterol and dual 
bronchodilator 
(LAMA+ ultra LABA) 
umeclidinium–
vilanterol 
Moderate 
to severe 
Phase III 
clinical 
trials 
A total 10,355 
patients of 
which 4151 
received triple 
therapy and the 
rest were 
administered 
dual therapy  
Once-daily triple 
therapy reduced 
moderate or severe 
COPD exacerbations 
and improved lung 
function and quality of 
life than both dual 
therapy. 
Singh et al 
TRILOGY 
Study             
[453] 
Once daily triple 
therapy 
(ICS+LABA+LAMA) 
with single inhaler 
containing ultrafine 
beclometasone 
dipropionate, 
formoterol fumarate, 
and glycopyrronium 
bromide compared to 
twice daily 
(ICS+LABA) 
beclometasone 
dipropionate and 
formoterol fumarate  
Moderate 
to severe 
Randomis
ed, 
double-
blinded 
active-
controlled 
trial done 
in 159 
sites 
across 14 
countries 
A total of 1367 
patients of 
which 687 
were on triple 
therapy and 
680 on dual 
therapy 
Triple therapy showed 
greater benefit than 
dual therapy in 
reduction of moderate 
to severe exacerbation 
and quality of life. 
Triple therapy 
effectively increased 
bronchodilation 
increased in patients 
with severe 
exacerbations 
however, no changes 
in dyspnea was 
observed 
43 
 
Papi et al 
TRIBUTE 
study       
[454] 
Once daily triple 
therapy 
(ICS+LABA+LAMA) 
beclometasone 
dipropionate/formoterol 
fumarate compared to 
(LABA+LAMA) 
indacaterol and 
glycopyrronium  
Moderate 
to Severe 
Phase 3b 
clinical 
trials done 
at 187 
sites 
across 17 
countries 
A total of 1532 
patients of 
which 764 
were on triple 
therapy and 
768 on dual 
therapy 
The triple therapy 
again was found to be 
effective in reducing 
the rate of moderate-
to-severe COPD 
exacerbations than 
dual bronchodilator 
combination, without 
increasing the risk of 
pneumonia 
Dual/monotherapy involving  ICS/LABA/LAMA comparative clinical studies 
Wedzicha 
et al 
FLAME 
study        
[455] 
Dual therapy with 
LABA indacaterol / 
LAMA glycopyrronium 
once  daily compared to 
LABA salmeterol + 
ICS fluticasone twice 
daily 
Moderate 
to severe 
A 
multicentr
e 
randomize
d, double-
blind, 
double-
dummy, 
parallel-
group, 
non-
inferiority 
trial 
A total of 3362 
patients 
underwent 
randomization; 
1680 were 
assigned to the 
indacaterol–
glycopyrroniu
m group, and 
1682 to the 
salmeterol–
fluticasone 
group 
Indacaterol–
glycopyrronium was 
consistently more 
effective than 
salmeterol–fluticasone 
in preventing 
exacerbations and was 
associated with no 
detectable increase in 
adverse events 
Anzueto    
et al         
[456] 
Comparison of dual 
therapy 
(LABA+LAMA) 
indacaterol and 
glycopyrronium(IND+
GLY) and  
monotherapy (LAMA) 
tiotropiun (TIO) 
(SHINE study)and dual 
therapy (LABA+ICS) 
salmeterol/fluticasone 
(SFC) (LANTERN 
study) 
Moderate 
to severe 
Multi-
centre, 
Phase III 
randomize
d clinical 
trial as 
part of 
IGNITE 
program 
A total of 954 
patients for 
SHINE study 
of which 474 
administered 
(IND+GLY) 
and 480 TIO 
monotherapy.  
In LANTERN 
study 1,263 
patients 630 
(IND+GLY)  
and 633 with 
SFC   
Dual bronchodilator 
therapy with 
IND+GLY offered 
significant benefits 
over treatment with a 
single-agent LAMA 
or a LABA/ICS both 
in terms of the 
incidence and time to 
clinically important 
deterioration (CID). 
Kardos et 
al FAVOR 
study        
[457] 
Comparison of dual 
therapy 
(LABA+LAMA) 
indacaterol and 
glycopyrronium 
(IND+GLY) and  
monotherapy (LAMA) 
tiotropium 
Moderate 
to severe 
This 
randomize
d, open-
label, 
multicente
r, 
crossover 
study was 
conducted 
at 18 
Total of 176 
patients 88 in 
each arm 
The combination of 
LABA/LAMA 
improved lung 
function in COPD 
patients compared to 
monotherapy with 
Tiotropium 
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centres in 
Germany 
Roflumilast (PDE4 inhibitor) in COPD clinical studies 
Martinez 
et al 
RESPON
D study 
[458] 
Roflumilast compared 
with placebo 
Moderate 
to Severe 
Phase IV 
multicentr
e, 
randomize
d, double-
blind, 
placebo-
controlled 
A total of 
2,354 COPD 
patients were 
randomized 
 1,178 treated 
with 
roflumilast and 
 1,176 placebo 
The study found 
roflumilast effective  
in reducing moderate 
to severe exacerbation 
and  was more 
pronounced in  
patients with history 
of COPD-related 
hospitalization and 
those with frequent 
COPD exacerbations 
Martinez 
et al  
REACT 
study 
[459] 
Roflumilast compared 
with placebo 
Moderate 
to Severe 
Phase 
III/IV 
multi-
center, 
randomize
d, double-
blind, 
placebo-
controlled 
1945 
participants, 
973 to the 
roflumilast 
group and 972 
placebos 
Roflumilast 
effectively reduces 
exacerbations and 
hospital admissions in 
patients with severe 
chronic obstructive 
pulmonary disease 
and severe 
exacerbations. 
Rabe KF 
et al  
ROBERT 
study 
[460] 
Roflumilast compared 
with placebo 
Moderate 
to severe 
and 
chronic 
bronchitis 
Double-
blind, 
placebo-
controlled 
trial done 
at 18 sites 
in five 
countries 
158 patients 
were randomly 
assigned: 79 to 
the roflumilast 
group, and 79 
to the placebo 
group 
16 weeks of treatment 
with roflumilast did 
not affect the number 
of CD8 cells in 
bronchial submucosa 
compared with 
placebo but reduced 
the eosinophil biopsy 
numbers 
Statins in COPD clinical trials 
Balaguer 
et al [461] 
Simvastatin compared 
with placebo 
Moderate 
to severe 
Randomis
ed control 
trial 
18 eligible 
participants. 9 
in each arm  
No significant change 
was observed on 
pulmonary/ systemic 
inflammation and lung 
function in 
simvastatin treated 
COPD patients 
compared to placebo.   
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